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tHis REPoRt is DEDicatED to
Margie Garber-Steinberg 
April 7, 1949 – April 14, 2016
this edition of the Pipeline Report is dedicated to Margie garber-steinberg,  
mother of long-time board member Jason osher. Margie was a steadfast  
tag supporter for well over a dozen years, and not only fought  
against the HiV/aiDs pandemic through her support and philanthropy, but  
also fought her own battle with cancer for ten years, undergoing two stem cell  
transplants and countless chemotherapies and drug combinations.  
she was a much adored wife, mother, grandmother, and friend.  
she was also a strong warrior, and showed us all how to continue to fight,  
despite the obstacles. Her love for tag and its leaders, her humor, and  
her voice to end HiV/aiDs will be sorely missed. 
 
tHis REPoRt is DEDicatED to
Paul Blanchard
1964 – 2016
the 2016 Pipeline Report is dedicated to i-Base co-founder Paul Blanchard (1964 -2016). 
Paul played a unique role in establishing treatment activism in the uK, challenging doctors to 
continually update their views and practice with evidence from rapidly evolving research.  
like many HiV activists Paul experienced the dramatic benefits of aRt first hand when 
antiretroviral therapy was very new. He was one of the leading activists to recognize the need to 
use triple combination therapy to achieve optimal and sustained viral suppression and  
to avoid drug resistance, when uK guidelines – and many other uK HiV organizations – 
suggested fewer drugs might be sufficient.
     Paul had a tremendous and steady intellect and a unique critical view that enabled him to 
comment on new advances and current practice with such masterly understatement that would 
make disagreeing with his conclusions extremely difficult.
     He also had a wicked sense of humor, writing an article on the increases in  
“internet-related stis” with a chuckle “because doctors love reading about this sort of thing” or 
commenting proudly on his own 7-drug salvage regimen in the late 90s that  
“none of them are made by glaxo Welcome”.
Paul will be deeply missed.
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The Tuberculosis Diagnostics Pipeline 
 
By Erica Lessem 
 
INTRODUCTION
Over the past decade, several new options for improving TB diagnosis have become available. The 
past year saw considerably more progress than the previous one. However, the reality of how most 
TB is diagnosed—or not—remains largely unchanged. The world failed to detect 3.6 million of the 
estimated 9.6 million new cases of TB in 2014.1 Sputum smear microscopy—which misses over half 
of TB cases2 and gives no indication of drug susceptibility to guide appropriate treatment—is still the 
diagnostic standard in most of the world, despite the availability of the far more sensitive GeneXpert 
MTB/RIF for six years.3 Late in 2015, the World Health Organization (WHO) approved Alere’s TB 
lipoarabinomannan (LAM) test—a very affordable, simple, rapid, noninvasive, point-of-care (POC) 
rule-in test for people with HIV with very low CD4 counts—but no country has begun to implement 
it yet. New versions of line probe assays—Hain’s MTBDRplus and MTBDRsl and a product from 
Nipro—received WHO recommendation, facilitating rapid drug susceptibility testing (DST), but the 
world is still a long way from universal DST, with an estimated 59 percent of cases of multidrug-
resistant TB (MDR-TB) undetected.4    
Research and development (R&D) for TB diagnostics features some promising developments since 
last year (see table 1). Improvements on nucleic acid amplification tests (NAATs) such as GeneXpert 
Omni and Ultra and Molbio’s TrueNAT are being validated, positioning them for possible WHO 
recommendation. Further upstream, encouraging research into gene sets that can predict active TB 
disease and reliably distinguish it from latent TB and other infections may eventually underpin new 
blood tests (currently, there is no effective serological test for active TB). Incremental advances are 
being made to improve detection of pediatric TB (see “Extending quality,” page 133).
Yet, overall, with a mere US$65 million in 2014 funding out of an estimated annual need of $340 
million,5  the pipeline for evidence-based new diagnostics has largely remained stagnant (see 
table 2). Dismayingly, some companies continue to move forward with marketing for their products 
when the data are unavailable or scream that they should not, as is the case with Epistem, which is 
marketing GeneDrive in India despite the test’s having flopped in studies. 
With use of poor tests predominating, poor uptake of good extant options, poor evidence bases to 
support the introduction of new tests, and poor funding to support the development of better tests, 
it’s no wonder we’ve made little headway in diagnosing TB. 
Help us improve this report by answering a short survey 
at: https://www.surveymonkey.com/r/TAGpipeline2016
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Table 1. 2016 Tuberculosis Diagnostics Pipeline: Products in Later-Stage Development or  
on Track for Evaluation by the WHO with New Published Data or Policy Updates Since 
the 2015 Pipeline Report
Test Type Sponsor Status Comments
MOLECULAR/NAAT
BD MAX MTB assay qPCR for MTB in automated BD MAX BD In 16 M. tuberculosis samples, 100% 
sensitivity,  97.1% specificity6
Genedrive MTB/RIF Portable RT-PCR for MTB +  
RIF resistance
Epistem Worse sensitivity than smear [!] in 2016 
study7
Marketed in India
GenoType MTBDRplus Line probe assay for RIF +  
INH resistance
Hain Lifescience WHO now recommends based on FIND 
evaluation8
WHO guidance pending
GenoType MTBDRsl Line probe assay for FQ +  
SLID resistance
Hain Lifescience WHO now recommends9 FIND’s multicountry 
evaluation of MTBDRsl 
version 2.0 from 2015 
still unpublished
MeltPro Closed-tube RT-PCR Zeesan Biotech New study from China of 2,057 smear-
positive TB patients shows sensitivity 
of detecting resistance to rifampin 
94.2%,  isoniazid 84.9%, ofloxacin 83.3%, 
amikacin 75.0%, kanamycin 63.5%10
NTM+MDRTB 
Detection Kit 2
Line probe assay for RIF + INH 
resistance





Automated RT-PCR for MTB; can be 
added to HIV RNA platform
Abbott Sensitivity 100%, 95% CI: 98.6–99.9 
in smear-positive samples, similar to 
GeneXpert MTB/RIF12
Truenat MTB Chip-based NAAT with RT-PCR on 
handheld device for MTB
Molbio Diagnostics, 
Bigtec Labs
FIND and ICMR studies underway
Xpert MTB/RIF Ultra Next-generation cartridge-based 
detection of MTB + RIF resistance
Cepheid FIND study results anticipated end 2016  
Xpert Omni Single-cartridge mobile platform 
that can use single MTB/RIF or Ultra 
cartridge 
Cepheid FIND study pending but delayed
Xpert XDR NAAT Cepheid FIND study anticipated 2018
ANTIBODY/ANTIGEN DETECTION
Determine TB LAM Ag Urine dipstick for TB LAM protein Alere WHO recommended use in people with 
HIV with CD4 count <10013
CI: confidence interval 
FLD: first-line drugs (isoniazid, rifampin, ethambutol, 
   pyrazinamide) 
FQ: fluoroquinolone 
ICMR: Indian Council of Medical Research 
INH: isoniazid 
LAM: lipoarabinomannan 
MDR-TB: multidrug-resistant tuberculosis 
MTB: Mycobacterium tuberculosis 
NAAT: nucleic-acid amplification test 
qPCR: quantitative polymerase chain reaction 
RIF: rifampin 
RT-PCR: real-time polymerase chain reaction 
SLID: second-line injectable drug (e.g., amikacin, 
   capreomycin, or kanamycin) 
WHO: World Health Organization
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Table 2. Later-Stage or Marketed TB Diagnostic Test Candidates with No New Published 
Evaluation Data
Test Type Sponsor Status
MOLECULAR/NAAT
EasyNAT Isothermal DNA amplification/lateral 
flow to detect MTB
Ustar No new data since poor in Tanzanian field study14
FluoroType MTB Semiautomated direct MTB detection; 
PCR in a closed system; results in 3 
hours
Hain Lifescience Marketed
FluoroType MTB RNA MTB RNA for monitoring of anti-TB 
therapy
Hain Lifescience No published data
GeneChip RT-PCR for RIF + INH DR CapitalBio Marketed
LATE-PCR with  
Lights-On/Lights-Off Probes 
+ PrimeSafe
Single-tube PCR to detect MTB, 





LiPA pyrazinamide Line probe assay for PZA resistance Nipro Marketed
PureLamp Manual NAAT by loop-mediated 
isothermal amplification for MTB 
detection
Eiken WHO June 2015 review impeded by data quality issues; 
guidelines development group reexamined evidence 
January 2016; recommendations expected June 2016 
REBA MTB-MDR Line probe assay for RIF + INH 
resistance
YD Diagnostics No new data; marketed
REBA MTB-XDR Line probe assay for FQ + SLID DR YD Diagnostics No new data; marketed
TREK Sensititre MYCOTB MIC 
plate
Dry microdilution plate to detect MICs 
for FLD + SLD (except PZA)
TREK Diagnostic Systems, 
Thermo Fisher Scientific
No new evaluation data but used in study in Cameroon15
TRC Rapid MTB Automated rapid rRNA to detect MTB Tosoh No new data
VOLATILE ORGANIC COMPOUNDS
Giant African pouched rats 
(Cricetomys gambianus)
Trained sniffer rats to detect MTB in 
sputum
Apopo Foundation No new data
AUTOMATED IMAGING
CAD 4TB Digital CXR for TB screening Delft Imaging Systems Marketed; in 2016 WHO to review available evidence on 
computer-aided radiographic TB detection and organize 
a scoping meeting to determine research needs and if 
guidelines should be developed16
ANTIBODY/ANTIGEN DETECTION
MBio Array System POC cartridge to measure ~57 





CXR: chest x-ray 
DR: drug resistance 
EMB: ethambutol 
FLD: first-line drugs (isoniazid, rifampin, ethambutol, 
   pyrazinamide) 
FQ: fluoroquinolone 
INH: isoniazid 
MDR-TB: multidrug-resistant TB 
MIC: minimum inhibitory concentration 
MTB: Mycobacterium tuberculosis 
NAAT: nucleic-acid amplification test 
PCR: polymerase chain reaction 
POC: point of care 
PZA: pyrazinamide 
RIF: rifampin 
RT-PCR: real-time polymerase chain reaction 
SLD: second-line drug 
SLID: second-line injectable drug (e.g., amikacin, 
   capreomycin, or kanamycin) 
TB: tuberculosis 
WHO: World Health Organization
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TROT, TROT TO MARKET
Perhaps the most exciting advance in TB diagnostics came in late 2015, when the WHO recommended 
Alere’s Determine LAM Ag simple urine dipstick test for ruling in TB in people with HIV with CD4 counts 
below 100/mm3 or who are seriously ill.17 The test’s imperfect sensitivity (56% pooled sensitivity based on 
five studies of people with CD4 counts below 100/mm3) means that a negative test must still be followed up 
with other testing to rule out TB.18 However, given the extremely high mortality of people with TB and HIV (TB 
is thought to be the cause of death in nearly 40% of HIV-positive patients, half of which is undiagnosed)19 
and challenges in diagnosing TB in people with low CD4 counts, having an inexpensive ($2.26 per test), 
simple, and noninvasive test to use in this very high-risk population is a major advance. In fact, the LAM test 
is the first TB test to ever demonstrate a mortality benefit in a randomized controlled clinical trial: among 578 
people with HIV in hospitals in South Africa, Tanzania, Zambia, and Zimbabwe, using LAM was associated 
with an absolute reduction of all-cause mortality at eight weeks of 4% (95% confidence interval [CI]: 1%–7%) 
from 25% to 21%, and a relative risk reduction of 17% (95% CI: 4%–28%).20 This difference appeared to 
be attributable to the test’s allowing earlier initiation (by one day on average) of anti-TB therapy.21 Countries 
with large burdens of TB/HIV, including many countries in sub-Saharan Africa, should roll out LAM testing 
immediately, along with proper accompanying training to ensure the test is used only in the recommended 
population and that follow-up tests are done as necessary.22 Whoever ends up with the rights to the test—
Abbott is trying to pull out of a putative acquisition of Alere—should ensure its continued manufacture as well 
as marketing.23 Further upstream, funding from the Global Health Innovative Technology Fund (GHIT Fund, 
which is itself funded by the Japanese government, pharmaceutical companies, the Bill & Melinda Gates 
Foundation, and the Wellcome Trust) to FIND and Fujifilm will support the development of what is hoped to be 
a more sensitive LAM test.24,25,26
Other policy advances can help improve timely detection of drug-resistant TB. In late 2015, the WHO 
extended its 2008 guidance, which recommended the use of the Hain version 1 line probe assay (LPA), to 
recommend the use of two alternative LPAs with the capability to detect TB and rifampin resistance: the Hain 
version 2 LPA (also called the GenoType MTBDRplus assay) and the Nipro Assay.27 The WHO still does not 
recommend using LPAs on smear-negative samples. In 2014 and 2015, FIND conducted a cross-sectional 
noninferiority study to compare the accuracy of these two tests to that of Hain Version 1 assay, evaluating 
their performance both on clinical isolates and on sputum specimens from people with pulmonary TB; 
both tests showed comparable performance in detecting Mycobacterium tuberculosis (the bacterium that 
causes TB infection and disease) and rifampin resistance in smear-positive samples: on clinical isolates, 
sensitivity and specificity compared with the phenotypic reference standard for Hain V1, HainV2, and Nipro 
were 90.3%/98.5%, 90.3%/98.5% and 92.0%/98.5%, respectively, for detection of  rifampin resistance 
and 89.1%/99.4%, 89.1%/99.4%, and 89.6%/100.0%, respectively, for detecting isoniazid resistance. In 
sputum testing, sensitivity and specificity were 97.1%/97.1%, 98.2%/97.8%, and 96.5%/97.5% for rifampin 
resistance and 94.4%/96.4%, 95.4%/98.8%, and 94.9%/97.6% for isoniazid resistance.28 The WHO will 
update its guidance on LPAs later in 2016. While this certainly reflects progress, Hain and Nipro launched 
these assays in 2011; it’s taken five years to optimize and fully evaluate them.
In May 2016, the WHO also recommended and issued guidance on Hain’s MTBDRsl, an LPA capable of 
detecting resistance to fluoroquinolones and second-line injectables.29 LPAs can produce results in 24–48 
hours, much quicker than the two weeks that liquid culture or two to three months that solid culture take. As 
such, the MTBDRsl LPA can guide appropriate treatment selection. The announcement of the WHO’s MTBDRsl 
recommendation accompanied its recommendation of the shortened or “modified Bangladesh” regimen, 
whose introduction the test can help facilitate, as the shortened (9- to 12-month) regimen is not suitable for 
fluoroquinolone- or injectable-resistant TB (pre-XDR-TB; see “Tuberculosis Treatment,” page 35).30 Countries 
and donors must scale up the introduction of this test and work with Hain to further reduce the price. FIND 
negotiated a public sector price of €7.50 (approximately $10) per test strip in 138 countries; however, the 
total cost of running a test (which requires other laboratory supplies) can result in costs of $20–$30. The test 
equipment itself can cost $8,000–$40,000, depending on its size and whether it automatically reads results or not.31 
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Newer iterations of GeneXpert are moving closer to market. Recent investments may make it more suitable for 
use in a variety of settings and more sensitive. GeneXpert Omni, a smaller and more rugged single-cartridge 
version of the test that is dustproof and runs on batteries could be a point-of-care test for TB. The test device’s 
anticipated cost is $2,895.32 Cepheid claims that another new product, the GeneXpert Ultra cartridge, is 
more sensitive than the MTB/RIF, approximating the sensitivity of culture, and has a shorter processing time.33 
FIND is currently validating both the Ultra cartridge and Omni platform: Ultra results are expected at the 
end of 2016; Omni results have been further delayed. If studies show them to indeed be as promising as the 
company claims, the WHO will issue recommendations and formulate guidance accordingly. Data on the 
use of Ultra in smear-negative specimens are expected in 2017, which could inform recommendations on 
whether Ultra can be used to replace culture. Cartridge prices are expected to remain consistently high at 
$9.99, as even though MTB/RIF sales volumes have increased,34 those profits are said (by Cepheid) to have 
been reinvested in R&D. In 2017, Cepheid plans to release the XDR assay, designed to genotype resistance to 
isoniazid, fluoroquinolones, and second-line injectables when MTB/RIF (or Ultra) indicates rifampin-resistant 
TB, though no peer-reviewed data yet exist on this product.35 A FIND evaluation is expected in 2018.
Molbio’s TrueNAT, an Indian GeneXpert competitor that has been on the market since 2013, is finally being 
validated by outside parties (FIND and the Indian Council on Medical Research).36 A recent study compared 
TrueNAT to Xpert MTB/RIF on 274 patient specimens, using culture as the reference standard. The assays had 
similar sensitivity on sputum-smear-positive samples: TrueNAT had 99% sensitivity (95% CI: 94.2%–99.95%) 
versus MTB/RIF’s 100% (95% CI: 96.5–100.0%, respectively). With sputum-smear-negative, culture-positive 
samples, the sensitivity of the TrueNAT was 86.2% (95% CI: 74.1%–93.4%) as compared with 90.1% (95% 
CI: 88.7%–94.35%) for Xpert MTB/RIF.37 The cartridge-based sample preparation extraction tool, TruePrep—
which is rugged and portable—costs $7,000, and each assay costs $14; the public sector will receive a 
further discount.38 
Other products without the data to back them up continue to be marketed by unscrupulous manufacturers. 
Epistem’s Genedrive performed dismally in a recent clinical study of 336 participants: sensitivity was 45.4%  
(95%CI: 35.2%–55.8%) versus 91.8% (95% CI: 84.4%–96.4%) for Xpert MTB/RIF and 77.3% (95% CI: 
67.7%–85.2%) for smear microscopy. In smear-negative cases, sensitivity of GeneDrive was 0% (95% CI: 0, 
15.4) versus 68.2% (95% CI: 45.1%–86.1%) for Xpert.39 Yet just after those data were published, Epistem 
announced full commercial launch of Genedrive TB tests in India, claiming it “enables early detection of TB 
and antibiotic resistance without need for central laboratory facilities.”40 The regulatory authority in India 
should ban the marketing of this test, and private providers should be extremely wary and not waste patients’ 
time, money, and effort by subjecting them to it (see box). 
Extending Quality and Affordability to the Private Sector 
Many countries, including 12 of the 22 countries with the highest TB burdens (India, Pakistan, the Philippines, 
Bangladesh, Afghanistan, Kenya, Uganda, Vietnam, Indonesia, Myanmar, Nigeria, and Cambodia) 
have large private-sector markets for TB diagnosis and care.41 Ensuring access to affordable, quality 
diagnosis is both critical and challenging. The use of unvalidated tests, or using tests off-label, can 
endanger patients and their communities and, at best, wastes their money and time. Important 
tests, such as GeneXpert, are not commercially available in the private sector in Burma, Cambodia, 
Indonesia, Nigeria, Uganda, or Vietnam.42 But even when good tests are available in the private sector, 
patients pay dearly, as concessional prices are normally available only to the public sector, and some 
private practitioners are aiming to maximize profit. For example, in Afghanistan, Bangladesh, India, 
Kenya, Pakistan, and the Philippines, GeneXpert is available, but the average price charged by private 
laboratories is $68.73 (range $30.26–$155.44).43 Private diagnosis without case notification to the 
public program also impedes getting a true picture of local, national, and global TB epidemiology. 
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In India, where about half of patients seek TB diagnosis and care in the private sector, the Indian 
government and other actors have taken steps to mitigate the inappropriate use of TB diagnostics, 
such as banning the use of serological tests and discouraging the use of Quantiferon TB Gold (a test 
for latent TB that was being inappropriately marketed and used in India to screen for active TB).44,45 
Efforts are underway to ensure best TB diagnostic practices among private-sector providers in India at 
an affordable price. The Initiative for Promoting Affordable and Quality TB Tests (IPAQT) offers WHO-
recommended TB diagnostics to laboratories who agree to pass on these price reductions to patients 
by agreeing to a maximum ceiling price, participating in quality assurance programs, and notifying 
cases to the public program.46 
To date, IPAQT has involved 116 laboratories across India, with over 250,000 presumptive TB cases 
tested, and volumes climbing. IPAQT has notified 23,000 cases in five cities under a pilot program 
and plans to further involve more decentralized laboratories and to streamline notification, as well as 
to look into expanding into cross-disease diagnostic support, such as including the HIV1 viral load 
GeneXpert cartridge in the IPAQT framework. Other countries with robust private-sector activity in TB 
should follow suit. The Clinton Health Access Initiative’s Nigeria team recently conducted an analysis to 
determine feasibility there.  
 
IN DEVELOPMENT
Back in the lab, a promising development came from a team at Stanford University that identified a three-
gene set indicative of active TB (GBP5, DUSP3, and KLF2) in whole blood across eight data sets containing 
over 1,000 samples from both adult and pediatric patients in ten countries. This gene signature could 
accurately separate people with active TB from healthy controls, from people with latent TB, and from 
people with other diseases. HIV status, bacillus Calmette-Guérin (BCG) vaccination, and drug resistance did 
not confound expression of the three-gene set. The gene set may be of use in monitoring treatment, as its 
expression increases with disease severity and decreases with time of treatment, though this must be validated 
prospectively. Further validation and development are required.47
Researchers from the University of Washington and the University of Cape Town have received funding to 
further study a simple oral swab to test for TB DNA, and it detected TB well in 18 of 20 patients in a proof-of-
concept study (90.0% sensitivity compared with GeneXpert MTB/RIF; 95% CI: 66.9%–98.2%).48,49
Several researchers are exploring the value of immune activation markers such as C-reactive protein (CRP) 
to indicate active TB disease or to identify good responses to TB therapy. One small study pre- and post-
treatment in Gambia showed that CRP levels showed the most significant decrease by two months of treatment 
(P < .0001), whereas two other markers, beta2 microglobulin and neopterin, showed little change by two 
months but a significant decrease by six months of treatment (P = .0002 and P < .0001, respectively).50 A larger 
prospective study identified a seven-marker biosignature including CRP as well as transthyretin, interferon-γ, 
complement factor H, apolipoprotein-A1, inducible protein 10, and serum amyloid A that identified TB 
disease in the test set (N = 210) with a sensitivity of 93.8% (95% CI: 84.0%–98.0%) and a specificity of 73.3% 
(95% CI: 65.2%–80.1%), regardless of HIV infection status.51 CRP may be of particular interest for pediatric 
development (see “Tuberculosis Diagnostics Research for Children,” page 7).
DST research saw some developments. Development of a rapid colorimetric method for detection of 
resistance to pyrazinamide—one of the most important drugs to treat TB, for which DST development remains 
challenging due to the enormous number of resistance-associated mutations in the M. tuberculosis pncA 
gene—using a dye called 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) progressed when initial testing in 
a small test of 50 isolates showed DST results could be available in four to six days with 97.1% sensitivity 
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and 81.3% specificity, in comparison with liquid culture.52 Unfortunately, research that could underpin DST 
development for bedaquiline has not yet been as successful—examining the 12 cases who had developed 
over fourfold increases in bedaquiline minimum inhibitory concentrations (MICs) in study C209 revealed that 
all had M. tuberculosis with mutations in the Rv0678 gene, but there was no correlation between MIC change 
and treatment response, making it unclear what might be a clinically meaningful breakpoint.53 Developing 
DST for bedaquiline will be important, as resistance to it has already started to develop.54
 
RECOMMENDATIONS
With new products moving forward and interesting new leads to pursue, we are pleased to report progress 
with the TB diagnostics pipeline. But the world is still far from ensuring all those with TB get appropriate 
diagnostics. Both R&D and access need dramatic infusions of funding and political will. In particular: 
•	 National governments and donors must substantially increase funding for TB programs to allow 
for best diagnostic practices. This includes the widespread scale-up of NAAT to supplant microscopy, 
universal DST using liquid culture or LPAs, digital X-ray, and the rapid adoption of LAM testing in areas 
with high HIV burdens.
•	 National governments, donors, and the private sector must invest far more in TB R&D to advance 
better tests, including those for children. This should include a commitment to rapidly and rigorously 
evaluating new technologies and to publishing peer-reviewed results. Greater resources are necessary to 
achieve the requirements set out in Target Product Profiles (TPPs).55
•	 National governments and donors should work closely with the nonprofit and private sectors to 
ensure only quality and affordable tests are used. In countries with large proportions of care-seeking 
in the private sector, access to appropriate diagnostics is extremely limited and can be catastrophically 
expensive. Good programs such as IPAQT to address this exist and should be expanded and replicated. 
•	 Developers must commit to timely and rigorous validations of their tests prior to marketing, 
and health and regulatory authorities and private practitioners should hold them accountable 
for doing so. Epistem and other companies who market ineffective or as-yet-unproven tests must cease 
doing so immediately. National governments should ban the import and use of inappropriate tests and 
enforce those bans. Those working in TB globally should call to task companies such as Epistem that 
inappropriately market them.
Tuberculosis Diagnostics Research for Children
By Lindsay McKenna
The ability to confirm the presence of tuberculosis (TB) bacteria in the body (microbiological diagnosis) 
underpins much of the existing technology and paradigm for diagnosing TB in adults, but this approach is 
problematic for children. An estimated 60 percent of children with TB go undiagnosed: in 2014, national 
TB programs reported 358,521 cases of TB among children to the World Health Organization (WHO),56 
yet credible models estimate that one million cases of incident TB occur among children each year.57 TB 
is also likely a major unrecognized co-morbidity or cause of illness and death among children affected 
by pneumonia, meningitis, HIV, and malnutrition.58 Children with the disease have fewer TB bacteria in 
their bodies (paucibacillary disease), difficulty producing sputum, and high rates of extrapulmonary TB. As 
a result, diagnosis is often empirical (presumed, rather than confirmed) and based on a combination of 
clinical and epidemiologic information.
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The gold standard for diagnosing TB, microbiological confirmation using culture, is only obtained in 15–
20% of children with clinically diagnosed TB disease.59 Compared with culture, Xpert MTB/RIF has 62% 
pooled sensitivity when performed on induced or expectorated sputum (36% more sensitive than smear 
microscopy) and 66% pooled sensitivity when performed on gastric aspirate or lavage (44% more sensitive 
than smear microscopy).60 Xpert MTB/RIF sensitivity in culture-negative children clinically diagnosed 
with TB is just 2% for induced or expectorated sputum.61 The WHO recommends Xpert MTB/RIF as the 
initial diagnostic test in children suspected of having multidrug-resistant TB (MDR-TB) or HIV-associated 
TB or, where resources allow, as the initial diagnostic test in all children suspected of having TB.62 These 
recommendations apply to both pulmonary and extrapulmonary specimens, with the exception of stool, 
urine, and blood, given the lack of data for the utility of Xpert MTB/RIF for these specimen types.63 It is 
important to note that a majority of studies evaluating Xpert MTB/RIF’s performance have been conducted 
at higher-level health facilities, where it is likely that sicker children with higher rates of smear-positive TB 
are present for evaluation. How Xpert MTB/RIF performs among children in an outpatient setting, and with 
different levels of TB disease severity, has not been well studied. That said, while Xpert MTB/RIF is superior 
to smear microscopy and helps provide rapid confirmation of disease, it should not be used as a rule-out 
test for TB in children: clinical evaluation remains important in diagnosing TB in children. 
Research is ongoing to determine the most feasible and sensitive combinations of tests and specimen types 
(including urine and stool) for diagnosing TB in children64; to compare the performance of smear, culture, 
and Xpert at baseline and during treatment; and to optimize specimen sample collection and processing 
to improve diagnostic yields in children. In addition to efforts to optimize existing tools, new technologies 
in the pipeline might also improve our ability to detect TB in children in the future. The WHO recently 
recommended molecular line probe assays (LPAs) for the rapid detection of resistance to second-line TB 
drugs, including fluoroquinolones and injectable agents in children with confirmed rifampin-resistant TB 
or MDR-TB, based on extrapolation from data in adults.65 Xpert MTB/RIF Ultra, currently under evaluation 
in adults, is expected to have increased sensitivity and ability to detect paucibacillary TB disease, which is 
common in young children. Xpert XDR is expected to improve our ability to quickly diagnose resistance to 
first- and second-line TB drugs. These advances, though extremely important, are incremental. To radically 
improve diagnosis of all forms of pediatric TB, a rapid biomarker-based test that does not rely on sputum 
and can be used at the point of care is necessary.66 
The discovery and validation of biomarkers for TB diagnosis and treatment monitoring in children is an 
urgent research priority. A blueprint for pediatric TB biomarker identification and development, resulting 
from a 2014 U.S. National Institutes of Health (NIH)-convened workshop, is a call to action. The 
blueprint identifies critical research needs, including enhancing the detection of pathogen biomarkers and 
identifying host biomarkers, and calls for collaboration to advance the field.67 Efforts by an NIH-organized 
working group are underway to harmonize pediatric biorepositories (specimen collection methods and 
clinical data collection) to optimize their use for the future discovery and development of TB biomarkers in 
children. 
Compared with adults, children have increased risk of progression from infection to active disease.68 
While it is possible to diagnose TB infection in children using biomarker-based tuberculin skin testing (TST) 
and interferon-gamma release assays (IGRAs), these tests have shortcomings, including their inability to 
differentiate between TB infection and disease, cross-reactivity with other mycobacteria, particularly for 
TST, and increased false-negative tests among immune-compromised children. The ability to differentiate 
between infection and disease and to identify children at increased risk of progression to active disease 
would improve feasibility and make more efficient the targeted provision of preventive therapy to child 
contacts of TB patients in high-burden settings. 
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Efforts to identify and validate biomarkers of TB disease and risk of progression in adults and children 
are ongoing and, if proven, will greatly improve the reliability and ease of TB diagnosis. However, drug-
susceptibility tests rely on microbiological samples. Where a microbiological sample cannot be obtained, 
biomarkers that enable treatment monitoring in children could provide an interesting opportunity to improve  
access to appropriate treatment. Select pediatric biomarker research highlights are presented below.
PEDIATRIC BIOMARKER RESEARCH HIGHLIGHTS
LAM
Because both children and people with HIV tend to have higher rates of extrapulmonary TB, it was 
expected that the lateral flow urine LAM assay (currently recommended in HIV-positive adults who have low 
CD4 counts or are seriously ill) would work well in children, too. However, the LAM test demonstrated poor 
sensitivity (48.3%) and specificity (60.8%) compared with culture in HIV-positive and HIV-negative children 
with TB.69 The WHO recommendation for LAM in people with CD4 counts <100 (or with advanced HIV 
disease) does extend to children, based on the generalization of data from adults, while acknowledging 
very limited data in children.
C-reactive protein 
C-reactive protein (CRP), a nonspecific marker of inflammation detectable in blood and measurable 
with existing assays at the point of care, has shown potential for screening for TB disease and indicating 
response to TB treatment in adults (see “In Development” in this chapter, page 6). In one study, CRP 
demonstrated 98% sensitivity and 59% specificity for TB among South African adults with smear-negative, 
culture-positive TB with or without HIV.70 A study to identify the expression patterns of biomarkers in the 
plasma of HIV-negative children in India with pulmonary and extrapulmonary TB compared with healthy 
controls found that children with active TB showed significantly elevated levels of CRP. These findings are 
not surprising, as a detectable difference in inflammation can be expected when comparing healthy and 
sick children. As such, CRP should be evaluated as a marker of active TB and for use in TB diagnostic 
algorithms in larger pediatric cohorts, inclusive of children with latent TB and other pulmonary infections 
and HIV.71
TAM-TB
Encouragingly, a novel T-cell activation marker-tuberculosis assay (TAM-TB) demonstrated 83.3% sensitivity 
and 96.8% specificity among children with TB symptoms compared with culture. The pediatric cohort (N = 
113) in this prospective proof-of-concept study included HIV-positive and HIV-negative children 6 months 
to16 years old. The combined use of the TAM-TB assay and Xpert MTB/RIF demonstrated 94% sensitivity 
compared with culture. TAM-TB is a rapid blood-based test with the potential to improve the detection of 
active TB in children; further refinement and testing, especially in HIV-positive children with low CD4 cell 
counts, are necessary.72 
RNA expression signatures
A genome-wide analysis of RNA expression in blood among children undergoing evaluation for TB,  
including those with HIV, identified a 51-transcript signature capable of distinguishing TB from other 
diseases and from latent TB infection. The 51-transcript signature demonstrated 82.9% sensitivity and 
83.6% specificity for culture-confirmed TB (Xpert MTB/RIF sensitivity was 54.3%). For culture-negative TB 
where children are deemed to have highly probable, probable, or possible TB, the 51-transcript signature 
had an estimated sensitivity of 62.5–82.3%, 42.1–80.8%, and 35.3–79.6%, respectively (estimated 
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sensitivity for Xpert MTB/RIF was 25%–35.7%, 5.3%–13.3%, and 0%, respectively). The 51-transcript 
signature distinguished TB from latent infection with a sensitivity of 94% and a specificity of 100%. The 
51-transcript signature identified higher proportions of culture-confirmed and culture-negative cases of TB 
than Xpert MTB/RIF; however, innovation is needed to translate transcriptional signatures into diagnostic 
tools for resource-poor settings—current methods used to detect RNA transcripts are complex and costly.73
Gene expression signatures 
A multicohort analysis of data sets available in two public gene expression microarray repositories 
identified a three-gene signature (GBP5, DUSP3, and KLF2) capable of diagnosing active TB in adults and 
children, irrespective of bacillus Calmette-Guérin (BCG) vaccination or HIV status. The TB score derived 
from the three-gene signature demonstrated 85 percent sensitivity and 93% specificity in a cohort made up 
of both healthy people and those with active TB, 80% sensitivity and 86% specificity in a cohort made up 
of people with latent or active TB, and 81% sensitivity and 74% specificity in a cohort made up of people 
with other diseases or active TB. The TB score showed a significant decreasing trend with progression of 
treatment, suggesting its potential as a biomarker of clinical response to treatment. However, TB scores in 
children with culture-negative TB were significantly lower than those in children with culture-positive TB. 
The TB score demonstrated 86% sensitivity and specificity for latent TB versus culture-positive active TB in 
children.74 A blood-based test offers much advantage over what currently exists, but the ability to detect TB 
in culture-negative children is extremely important, limiting the potential utility of this three-gene signature 
for children with culture-negative TB, who account for 80% of children with TB.
RECOMMENDATIONS FOR PEDIATRIC TB DIAGNOSTICS
Much work remains to develop novel diagnostic technologies to accurately detect TB infection and 
disease; to predict disease progression in healthy, infected children; and to monitor treatment in children. 
The few tests that have been validated and recommended for use in children, including Xpert MTB/RIF, 
are sub-optimal and underutilized, partly due to difficulties with specimen collection. At the same time, 
efforts to identify children at risk for TB—especially within maternal and child health programs, where 
sick children often first present for care—and referral systems and decentralized capacity to diagnose 
childhood TB, clinically or with available tools, are urgently needed. We also need: 
•	 To validate tests in adults and children in parallel to expedite access to improved diagnostic 
technologies for children. These evaluations should include a variety of sample types in children with 
and without HIV and should assess age-related performance;
•	 Increased investments in research to discover and validate biomarkers and innovation to translate 
these biomarkers into simple and affordable tests that can rapidly and accurately diagnose TB, 
monitor treatment, and predict disease progression in children. In 2014, less than $2.3 million and 
$2.8 million was spent globally on research and development for pediatric TB diagnostics and basic 
science, respectively;75
•	 To establish and support harmonized and collaborative pediatric biorepositories important for 
biomarker discovery and development;
•	 To support and create networks of sites that support field evaluation of new diagnostics and can pool 
data to more rapidly demonstrate the impact of new tools;
•	 To scale up and decentralize the use of existing technologies and strategies to diagnose pediatric TB 
infection and disease, especially within maternal and child health programs; and
•	 To train health care workers to improve their ability and confidence to clinically diagnose children with 
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After decades of receiving short shrift from most national TB programs and international organizations, 
tuberculosis (TB) prevention is finally coming into the mainstream. In 2015, the World Health Organization 
(WHO) published its first-ever Guidelines on the Management of Latent Tuberculosis Infection.1 The launch 
of these guidelines has awakened countries and donors to the idea that TB prevention is an area ripe for 
intervention—and for intensified research. In March 2016, the executive board of the global health financing 
mechanism UNITAID endorsed TB prevention as one of three “areas for intervention” that should be prioritized 
for targeted investments in its TB portfolio.2 This support will likely include funding for research projects 
seeking to shorten and simplify preventive therapy for the groups that are most at risk of developing active 
TB disease: children and people with HIV. On the other side of the Atlantic, the U.S. White House’s National 
Action Plan for Combatting Multidrug-Resistant Tuberculosis lists TB prevention—specifically, “increasing 
options for preventing active TB, latent TB infection, and TB transmission”—as the first objective toward its 
goal of accelerating basic and applied research to overcome the threat of drug resistance.3 
As exemplified by these new guidelines and plans, a more focused TB prevention research agenda is 
beginning to take shape. This agenda involves tackling TB infection from two angles. First, preventive therapy 
is used to keep asymptomatic infection with Mycobacterium tuberculosis (MTB) from progressing to active, 
symptomatic TB disease. Second, vaccination is administered either pre-exposure to prevent infection with 
MTB altogether, or post-exposure to prevent infection from developing into disease. To date, research and 
development (R&D) on TB preventive therapies and vaccines have progressed with little interaction, despite the 
common goal of using new preventive therapies and vaccines to greatly hasten the decline in TB incidence 
by reducing the number of people with MTB infection who may one day develop transmissible disease. 
Indeed, mathematical modeling shows that the dramatic reductions in TB incidence required to meet the TB 
elimination targets of the WHO’s End TB Strategy will require addressing TB infection—first through preventive 
therapy and then through vaccination.4 
To acknowledge the momentum building behind TB prevention as a unified field of research, this year’s 
Pipeline Report jointly reviews progress in the clinical development of TB preventive therapy and TB vaccines. 
(Advances in infection control—the administrative, environmental, and personal protective measures 
that reduce the risk of TB transmission in the built environment—fall outside of the biomedical focus of 
this chapter.) There is much to be gained from breaking the habitual thinking that has placed TB drug 
development in one camp and vaccines in another. For one, a joint discussion reveals that initiatives to 
develop new TB preventive therapies and vaccines face a shared thicket of thorny scientific issues, whose 
lack of resolution has snarled progress toward both ends. Approaching TB preventive therapy and vaccines 
as related endeavors may also jumpstart an advocacy movement for TB prevention that is more forceful than 
disjointed efforts to hold public and political attention on separate technological fixes (an approach that can 
sometimes be misinterpreted by politicians as an either/or choice between treatment and prevention). Finally, 
prevention research raises a number of unique ethical considerations, with corresponding implications for 
engaging communities in TB research that both drug and vaccine developers will need to address. 
 
PROGRESS IN TB PREVENTION SCIENCE
Developing new tools to prevent TB will require an intensification of basic science research that can inform 
product development, so it is fitting that some of the most notable achievements over the past year have 




come from the laboratory. Scientists are employing a range of tools to shine new light on how MTB interacts 
with its human host—sometimes literally, as with the application of positron emission tomography (PET) and 
X-ray computed tomography (CT) to visualize and map inflammation-based immune activity to MTB as it 
unfolds across the geography of the lung.5 An array of studies—some in animals, others in humans; some 
observational, others experimental—are illuminating the hidden corners of genome, blood, and lung to 
improve our understanding of the dynamic nature of MTB infection, how it progresses over time, and why it 
sometimes spills over into active TB disease. 
 
Predicting Disease Progression through Gene-based Signatures of Risk
The central challenge in TB prevention research is that scientists have yet to establish a firm link between 
the appearance of any specific biomarker in individuals with asymptomatic MTB infection and progression 
to active TB disease. Biomarkers are measurable characteristics, such as gene activity, biological processes, 
or clinical phenotypes, whose presence signifies either a particular disease state or the body’s response to 
vaccination or drug therapy.6 The quest to identify biomarkers that act as prospective signatures of risk for 
developing TB disease among individuals infected with MTB has animated much of TB prevention research.7,8 
Current methods for diagnosing MTB infection—the tuberculin skin test (TST) and interferon-gamma release 
assays (IGRAs)—cannot predict whether individuals with MTB infection will develop TB disease. (An estimated 
10% of MTB-infected people will develop active TB at some point in their lifetimes.9) 
Once validated in late-stage clinical trials, a biomarker that could reliably predict disease progression or 
distinguish between individuals with high or low risk would be a powerful tool for guiding public health 
intervention efforts by identifying individuals most in need of preventive therapy, thereby creating opportunities 
to interrupt transmission by preempting disease progression. Biomarker-guided interventions might require 
fewer resources than less-targeted approaches by placing only those people most likely to progress to disease 
on treatment. More immediately, a biomarker of prospective risk could streamline the clinical development 
of new TB vaccines and preventive therapies by allowing clinical trials to enroll persons with the greatest 
risk of developing active TB disease. This targeted approach would reduce the costs of research by allowing 
investigators to conduct smaller, more quickly enrolling studies.10 
Biomarker identification efforts took a significant step forward in 2016 with the publication of a prospective 
cohort study of over 6,000 South African adolescents with MTB infection.11 Investigators reported discovering 
a blood-based RNA signature comprised of 16 genes that predicted the risk of TB disease progression over 
a two-year period. These 16 genes, collectively referred to as a gene signature, appeared to be more active 
in 46 adolescents who developed TB than in 107 matched controls who remained healthy. Notably, the 
gene signature’s predictive power increased when measured at time points closer to TB diagnosis (sensitivity 
of 71.2% at 6 months before diagnosis compared with 62.9% at 6 to 12 months and 47.7% at 12 to 18 
months, reported at a specificity of 80%).12 
To validate these results, researchers tested the gene signature in two separate cohorts of HIV-negative adult 
household contacts of people with pulmonary TB: one from South Africa and the other from The Gambia. 
Successful validation in these cohorts led the investigators to ask two additional questions. First, given that 
sensitivity increased closer to diagnosis, could this signature of risk discriminate between MTB infection and 
active TB disease? When applied to published data from other adult cohorts in the United Kingdom, South 
Africa, and Malawi, the gene signature distinguished active TB from both MTB infection and other pulmonary 
diseases, including in people coinfected with TB and HIV (a population that usually presents more diagnostic 
challenges).13 Second, could a risk signature found in adolescents perform well in younger children? Here, 
too, the researchers found that the signature could distinguish between MTB infection and culture-confirmed 
TB disease in children (but not culture-negative TB). Children with culture-positive TB have more bacteria in 
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their lungs than those with culture-negative disease; thus, the signature’s discriminatory capability in this group 
suggests that activity in these 16 genes might be related to the number of replicating bacteria in the lung  
(i.e., bacterial load). Consistent with this idea, the gene signature gradually disappeared when researchers 
looked for it in patients receiving treatment for drug-sensitive TB.14 
Discovery of this 16-gene risk signature was made possible by the kind of collaborative team science that 
requires time and sustained financial support. The cohort of South African adolescents that provided data 
for the primary analysis enrolled its first participant in 2005 and completed follow-up in 2009.15 That means 
that the adolescents who participated in the study are now adults. No doubt many have since fallen sick from 
TB, and some may even have died from it. To build on the contribution of these then-teenagers, investigators 
should continue to follow them into adulthood to understand how risk of disease progression changes over 
the life cycle. Evaluating how well this risk signature performs in a larger number of participants drawn from 
a more general population with less exposure to TB is also important, as biomarker identification studies may 
have cohort biases that limit their generalizability across different populations.16 This cohort drew adolescents 
from an area with an extraordinarily high TB incidence rate (1,400 per 100,000 people), where the 
lifetime risk of progressing from MTB infection to TB disease far exceeds the 10% risk observed in any given 
population.17 
 
Failures of Translation between Markers in the Blood and Events in the Lung
One lingering question from this genetic risk signature study is the extent to which a signature identified 
from the blood reflects concurrent pathogenesis in the lung. Scientists are increasingly recognizing how the 
initial lung environment encountered by MTB is important for determining the outcome of infection, but these 
processes may not be well represented by immune cells circulating in peripheral blood.18,19 Acknowledging 
this limitation, investigators countered that circulating white blood cells “can serve as sentinels of lung 
pathophysiology.”20 However, the fidelity with which measurements taken from peripheral blood mirror disease 
processes unfolding in the lung remains far from settled.21 Long-held assumptions about the relationship 
between lung and blood in TB are being rethought on the basis of evidence from a range of studies (many in 
nonhuman primates) that is rewriting the script on the classic symbol of TB pathology, the granuloma, and its 
role in disease progression.
Granulomas (TB’s signature pulmonary lesions) are organized collections of macrophages and other immune 
cells that flock to sites of MTB infection in the lung. Traditional thinking has likened granulomas to immune 
fortresses that serve an essential protective function by containing MTB in a quiescent state. In the canonical 
view, people who develop active TB mount a less-effective immune response than individuals who maintain 
MTB infection without falling ill. This implies that different granulomas in a given individual all behave 
similarly, and that differences in granuloma activity between individuals result in one of two divergent clinical 
outcomes: latent infection or active disease.22   
Nothing seems so simple anymore. As one recent review put it, “the clinical hallmark of TB is the 
granuloma….[Yet] the field is even at a loss as to whether granuloma formation ultimately benefits host 
or bacterium, and which is the master of the situation.”23 Under certain conditions, granulomas appear to 
offer MTB a niche in which it can replicate and persist, whereas the granuloma at other times becomes the 
focal point at which immune cells marshal a coordinated response to control MTB.24 Whether a granuloma 
becomes a site of vulnerability or protection appears to depend on the nature of the local CD4+ T-cell 
response, particularly the ratio of pro- and anti-inflammatory cytokines present in the granuloma.25  
CD4+ T cells are critical for immunity against TB, and TB vaccine research has focused on achieving 
protection through cell-mediated immunity by developing vaccines that trigger CD4+ T cells to release 
type 1 helper (TH1) cytokines such as interferon-gamma (IFNγ), tumor necrosis factor-alpha (TNFα), and 
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interleukin-2 (IL-2).26 (Cytokines are small proteins that call and direct the behavior of other immune cells.) 
However, because immune responses to TB are usually measured in blood—which is easier to collect from 
humans than lung tissue—not much is known about the profile of local T-cell responses in the granuloma 
itself.27 
A clearer picture is starting to form from a series of studies in cynomolgus macaques, which have become 
an important animal model for TB prevention research, as they can develop either clinically active TB disease 
or latent TB infection with granulomas similar to those seen in humans.28 In addition, the MTB epitopes 
recognized by human CD4 T cells overlap substantially with those in macaques.29 (Epitopes, or small cell-
surface proteins, are the parts of antigens that are recognized by immune cells). Research summarized in last 
year’s Pipeline Report shows that a spectrum of lesion activity exists in individual macaques with either active 
disease or latent infection. Animals with active TB disease can have sterilized lesions, but, critically, they also 
contain a number of granulomas in which infection is not controlled, resulting in disease progression.30 This 
spectrum of activity in an individual suggests that the outcome of MTB infection is determined locally at the 
level of the granuloma and not systemically, where the immune response is more conveniently sampled from 
circulating blood. What controls infection at the granuloma level, and to what extent is this local response 
represented by immune readouts taken from the blood? 
One recent study in MTB-infected macaques sought to answer this question by comparing the T cells and 
cytokines found in granulomas to those observed in circulating blood.31 Investigators used PET/CT imaging  
to track granuloma formation in 28 cynomolgus macaques, 13 of which developed active TB disease and  
15 of which remained latently infected. After macaques were necropsied (killed), granulomas identified by 
PET/CT underwent histological examination, quantification of bacterial burden, and immunological analysis 
to measure the presence of pro-inflammatory cytokines (IFNγ, IL-2, TNF, and IL-17) and the anti-inflammatory 
cytokine IL-10.32 The results add several layers of complexity to our understanding of how cell-mediated 
immunity operates locally in TB. In a particular macaque, different granulomas exhibited highly variable 
cytokine profiles. Most T cells in granulomas produced a single type of cytokine (i.e., were monofunctional), 
but granulomas themselves contained a mix of T cells that produced different cytokines.33 (This stands in 
contrast with the stated intention of many TB vaccine studies, which judged the immunogenicity of vaccine 
candidates by looking for polyfunctional T cells in blood.34) Granulomas in which T cells produced both  
pro- and anti-inflammatory cytokines were more likely to be sterile or have lower bacterial burdens.35  
This is consistent with an emerging consensus that stimulation of pro-inflammatory cytokines such as IFNγ is 
necessary, but not sufficient, for protection; there must be a counterpoint to inflammatory activity, as too much 
can damage the lung and impair protection.36 Finally, in most of the macaques, T-cell responses measured 
in circulating blood (the systemic immune response) did not closely mirror T-cell responses observed in 
granulomas (the local immune response).37 
A related study in macaques probed the differential fates of granulomas from the perspective of MTB itself.38 
Investigators added genetic barcodes to individual MTB isolates, tracked the formation of lesions using PET/
CT, and, after necropsy, quantified the relative frequency of each MTB barcode in different lesions. They 
observed that most granulomas were founded by a single bacterium and that bacterial burden varied greatly 
across lesions, even in the same animal.39 Differences in bacterial burden may reflect variability in the killing 
efficacy of the immune response at the level of the individual lesion, as animals with active disease also 
had sterilized granulomas. Given this heterogeneity, the investigators commented that “it is not surprising 
that relevant predictors of disease outcome have been hard to identify from peripheral measures of immune 
response.”40 
The combination of PET/CT, genetic barcoding, and histopathology has revealed that, so long as TB vaccine 
developers continue to measure success through blood-based immune assays, they risk overlooking important 
details of what effective immunity against MTB looks like at sites of infection in the lung.41 Although it is now 
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possible to closely examine lung responses in nonhuman primates, investigators working in the clinic have 
few alternatives at hand. Some have predicted that PET/CT may one day be used in clinical trials to track 
biological signals of an effective vaccine. These signals might include observing fewer granulomas form 
early in infection, no dissemination of granulomas after infection, or lower levels of lung inflammation—as 
indicated by radiological markers picked up by PET/CT (e.g., 18-F fluorodeoxyglucose). However, due to 
concerns about exposing humans to repeated radiation without clear therapeutic necessity, PET/CT cannot 
be applied for routine monitoring in large clinical trials, and, even if the technique could, the composite 
vision of inflammation produced by PET/CT is not yet well enough defined to serve as a reliable surrogate 
of protection, much less a clinical trial endpoint. Other sampling methods, such as bronchoalveolar lavage 
(BAL)—a technique used to sample cells from the airway—yield closer approximations of the lung environment 
than blood, but there may be important differences between T cell responses in the airway and lung that 
make BAL an imperfect alternative.42 In addition, given that BAL requires passing a bronchoscope through 
the mouth or nose into the lung, it may be too invasive to perform on the scale of a clinical trial. Although 
formidable, these limitations should not inspire a sense of futility among vaccine developers. Work to develop 
blood-based assays that provide indications of vaccine-induced immunity in the lung should be a priority for 
the field. Using assays that measure more than IFNγ and other TH1 cytokines may also yield a more complete 
picture of vaccine-driven immune responses for guiding clinical development. 
 
Bacterial Individuality and Persistence
The ability to attach genetic barcodes to individual bacteria, as described above, has made it possible to 
speak of bacterial individuality and recognize that, just as not all granulomas behave identically, not all MTB 
cells are homogenous.43 Most MTB cells are susceptible to the bactericidal effects of the immune response 
or antibiotic therapy, but in any given population of MTB, a few bacteria are able to survive these assaults. 
Sometimes referred to as persisters, these bacterial survivors are slow-growing, nonreplicating, and thought to 
develop noninheritable resistance to antibiotics and the body’s adaptive immune response.44 The recalcitrance 
of these persisters contributes to the lengthy duration of treatment for both TB disease and MTB infection, 
and likely gives rise to a range of observed phenomena in TB infection and disease, from latency to disease 
progression to posttreatment relapse.45,46 
Understanding the biological mechanisms of persistence and how to overcome them is a major priority for 
TB drug developers working on prevention. Several TB drug research networks have formed scientific working 
groups to address the problem of persisters, and the topic has featured prominently in satellite meetings 
organized by the WHO at the 2014 and 2015 Conference on Retroviruses and Opportunistic Infections.47,48 
Of immediate concern for the development of new TB preventive therapies, some drugs may be more effective 
against persisters than others. For example, drugs with sterilizing activity such as rifapentine and pyrazinamide 
appear to be more capable of killing persistent organisms than bactericidal agents such as isoniazid, which is 
thought to be more active against replicating bacteria.49 Research into MTB persistence has also raised more 
fundamental questions, leading many scientists to ask, “What is latency anyway?” The initial challenge has 
been to disentangle terminology that is often conflated in the drug development vernacular—for example, the 
terms latency, persistence, and dormancy, which likely point to related, yet distinct, concepts.50 
 
PROGRESS IN TB VACCINE DEVELOPMENT 
The past year has served as the opening chapter in the TB vaccine field’s “shift to the left,” a strategy in 
which major funders such as the Bill & Melinda Gates Foundation are moving resources to basic discovery, 
preclinical development, and phase I and II trials (events located on the left side of the clinical development 
pipeline).51 No new vaccines have entered clinical testing since TAG’s 2015 Pipeline Report, although many 
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of the 14 candidates in the pipeline have initiated new trials (see table 1). Thus far, the thrust of activity under 
this shift to the left has been directed toward two tactics: experimental medicine studies and novel clinical 
trial designs. Taken together, the intention behind deploying these tactics is to first generate a more diverse 
stable of vaccine concepts, and then to more efficiently triage these in early-stage trials so that only the 
most promising candidates advance to larger, costlier efficacy trials.52 This strategy aims to correct a glaring 
weakness in the composition of the TB vaccine pipeline: the viral-vectored and adjuvanted subunit vaccines 
under development were all designed to play the same notes, just in slightly different combinations. For 
example, six of the eight subunit vaccines contain an Ag85 antigen (either Ag85A or Ag85B), and the majority 
of candidates were designed to provoke cell-mediated immunity driven by CD4 and CD8 T cells, resulting in 
vaccines with little immunologic diversity.53 
Table 1. TB Vaccines in Development
Agent Strategy Type Sponsor(s) Status
M. vaccae Immunotherapeutic Whole-cell M. vaccae AnHui Longcom Phase III
M72/AS01 Prime-boost Protein/adjuvant GlaxoSmithKline, Aeras Phase IIb
H4 + IC31 Prime-boost Protein/adjuvant Statens Serum Institut (SSI), 
Sanofi Pasteur, Valneva, Aeras
Phase IIa
H56 + IC31 Prime-boost Protein/adjuvant SSI, Valneva, Aeras Phase IIa
MTBVAC Prime Live genetically attenuated 
M. tuberculosis (MTB)
University of Zaragoza, Biofabri, 
TuBerculosis Vaccine Initiative 
(TBVI)
Phase IIa
VPM1002 Prime Live recombinant rBCG Serum Institute of India, Vakzine 
Projekt Management, TBVI, Max 
Planck Institute for Infection 
Biology 
Phase IIa
Dar-901 Prime-boost Whole-cell M. obuense Dartmouth University, Aeras Phase IIa 
ID93 + GLA-SE Prime-boost Protein/adjuvant Infectious Disease Research 
Institute, Aeras
Phase IIa
RUTI Immunotherapeutic Fragmented MTB Archivel Farma Phase IIa
Ad5Ag85A Prime-boost Viral vector McMaster University, CanSino Phase I
ChAdOx1.85A + 
MVA85A
Prime-boost Viral vector Oxford University Phase I 
MVA85A (aerosol) Prime-boost Viral vector Oxford University Phase I
MVA85A-IMX313 Prime-boost Viral vector Oxford University, Imaxio Phase I





Experimental Medicine Studies 
Experimental medicine refers to studies in humans—usually small and often nested into larger clinical trials—
that are intended to ask and answer scientific questions that may inform vaccine discovery and product 
development.54 These studies take advantage of opportunities to work in humans to further our understanding 
of the biological mechanisms underlying infection and disease. For the purposes of TB vaccine R&D, one 
major objective of experimental medicine studies is to develop new vaccine concepts by looking beyond 
immunity mediated through CD4 and CD8 T cells to consider other cell types (e.g., γδ T cells, mucosal-
associated invariant T cells, CD1-restricted T cells, antibodies produced by B cells, etc.).55 The overarching 
goal is to elevate the role of biological investigation in TB vaccine R&D and, in doing so, refashion product 
development from a strictly linear pathway to an iterative exchange between clinical work in humans, 
preclinical testing in their animal model counterparts, and basic research in vitro.56 
Vaccine developers have already responded to the call to incorporate experimental medicine into clinical 
testing. For example, Aeras is working with the HIV Vaccine Trials Network of the U.S. National Institutes of 
Health (NIH) on an immunology study that aims to better understand the assays used to assess the immune 
responses generated by subunit vaccines that are currently in the pipeline.57 In this study, South African 
adolescents will receive either the H4 + IC31 vaccine, the H56 + IC31 vaccine, or revaccination with 
bacillus Calmette–Guérin (BCG), the existing TB vaccine, which was first licensed in 1921 and used to prevent 
severe forms of TB in children. This is not a head-to-head trial between H4 + IC31, H56 + IC31, and BCG; 
rather, blood will be sampled at different time points and analyzed to generate a trove of immunological 
data on vaccine responses using validated and exploratory assays that may one day be evaluated as possible 
correlates of risk or protection.58,59 There is interest in conducting similar experimental medicine studies 
involving whole-cell mycobacterial vaccines.60 In such studies, the goal would be to refine assays to better 
distinguish the immune response provoked by whole-cell vaccines from that stimulated by BCG, or to develop 
assays to measure the activity of unconventional T cell subsets such as γδ T cells or CD1-restricted T cells.  
The field aspires to initiate one to two experimental medicine studies per year, and although each will 
have its own sharp focus, the overarching goal is to probe important scientific questions and increase our 
understanding of the biology of MTB infection in humans.61  
 
Novel Clinical Trial Designs
In parallel with experimental medicine studies, vaccine developers are employing novel clinical trial designs 
in early stages of testing. This has mostly entailed getting creative with clinical trial endpoints by designing 
phase IIa trials around the primary outcome of prevention of MTB infection as opposed to prevention of 
TB disease.62,63 As with any departure from convention, this strategy offers both risk and reward. Unlike TB 
disease, which can be microbiologically confirmed through diagnostic tests such as GeneXpert/MTB RIF or 
mycobacterial culture, MTB infection is difficult to reliably identify with extant tools. Prevention-of-infection 
trials define infection using blood-based IGRAs such as Qiagen’s QuantiFERON Gold In-Tube (QFT-Gold), a 
test that converts from negative to positive when it detects cell-mediated immune responses (i.e., IFNγ) to MTB 
antigens.64 However, the well-documented variability of IGRA results, and the potential of a positive IGRA 
to sometimes revert to negative after repeat testing, means that investigators must proceed cautiously.65,66,67 
Without a gold-standard diagnostic test for MTB infection, and without validated correlates of protective 
immunity, regulatory authorities are unlikely to license a new TB vaccine that is based on endpoints other than 
prevention of disease.68 
As a result, prevention-of-infection is not being pursued as a licensable vaccine indication, but rather as a 
tool for winnowing vaccine concepts before mounting efficacy studies with traditional prevention of TB disease 
endpoints. Given that infection with MTB is a more common occurrence than TB disease, prevention-of-
22
2016 PIPELINE REPORT
infection trials promise to save money by enrolling fewer participants in less time.69 The first results from this 
approach may be just around the corner. Aeras is conducting a three-arm phase IIa study of H4 + IC31 
and BCG revaccination in 990 BCG-vaccinated, HIV-negative adolescents in South Africa’s Western Cape 
province.70 The H4 + IC31 candidate pairs MTB antigens Ag85B and TB10.4 with IC31, an adjuvant owned 
by Valneva. One-third of participants will receive two doses of H4 + IC31, one-third will be revaccinated with 
a single dose of BCG, and the final third will receive two doses of placebo.71 The primary outcome is MTB 
infection, as defined by sustained IGRA conversion (in this case, QFT-Gold), and the primary analysis will 
occur when the study accrues 64 cases of MTB infection. Aeras reports that it is close to reaching this point 
and expects to release the results in 2017.72  
The subunit vaccine H56 + IC31, developed by the Statens Serum Institut of Denmark (SSI), will soon be used 
in a prevention-of-infection trial in Tanzania. H56 + IC31 consists of three MTB antigens (Ag85B,  
ESAT-6, and Rv2660c) paired with Valneva’s IC31 adjuvant. Given that the ESAT-6 antigen is present in both 
the H56 vaccine and the QFT-Gold test, the SSI first had to develop an IGRA without ESAT-6 before it could 
study H56 in a prevention-of-infection trial.73 (Using QFT-Gold to measure MTB infection in participants 
vaccinated with H56 could result in false positives, as the ESAT-6 in H56 could prime the antigen-specific 
T cells that the test looks for as an indication of MTB infection). The resulting ESAT-6-free IGRA contains 
four antigens (CFP10, QTC6, QTC7, and QTC13) and has been evaluated in studies in Denmark, Egypt, 
Tanzania, and South Africa; its performance appears to be on par with that of QFT-Gold.74 This ESAT-6-free 
IGRA was developed as a companion diagnostic for the H56 vaccine and is not intended to be a commercial 
alternative to QFT-Gold.75 The trial in Tanzania will contain two arms—one with H56 and the other with 
placebo—and enroll 1,400 adolescents. Aside from the lack of a third arm looking at BCG revaccination, 
the major difference between this study and the H4 prevention-of-infection trial is that the incidence of MTB 
infection in this part of Tanzania is much lower than that in South Africa’s Western Cape.76  
In addition to prevention of infection, TB vaccine developers are designing trials to evaluate prevention of 
recurrence, defined as either reactivation of disease from latency (i.e., relapse) or reinfection with MTB after 
treatment completion.77 Similar to MTB infection, the incidence of recurrent TB disease is higher in any given 
population than new cases of TB. Anywhere from 2–8% of treated TB patients will face recurrent disease, 
and the vast majority of these cases occur in the first 12 months after completing therapy.78,79 Consequently, 
prevention-of-recurrence trials offer similar advantages as prevention-of-infection trials in terms of 
demonstrating the mettle of vaccine candidates before selecting which ones to move forward to efficacy trials 
looking at prevention of disease. Successful prevention-of-recurrence trials might also create a pathway for 
developing therapeutic vaccines to either shorten the duration of treatment or bolster chemotherapy.80 
Several prevention-of-recurrence studies are under way. A phase IIa prevention-of-recurrence trial was recently 
begun for the subunit vaccine ID93 + GLA-SE in 60 South African adults who successfully completed therapy 
for drug-sensitive TB (DS-TB). Developed by the Infectious Disease Research Institute (Seattle, Washington), 
ID93 + GLA-SE combines the MTB antigens Rv2608, Rv3619, and Rv3620 with the GLA-SE adjuvant. The 
trial contains four arms and is testing two intramuscular injections of vaccine—given at three different doses—
against placebo (saline solution). This safety and dose-ranging study will inform planning for a phase IIb 
prevention-of-recurrence trial of ID93 + GLA-SE that will enroll up to 450 adults per arm.81 In addition to 
ID93 + GLA-SE, H56 recently completed enrollment in a phase I safety, immunogenicity, and dose-escalation 
study among 24 HIV-negative adults that were previously treated for DS-TB; results are forthcoming.82 H56 
+ IC31 is being studied as an adjunct to TB therapy when paired with COX-2-selective inhibitors (a type of 
nonsteroidal anti-inflammatory drug).83 The idea is that COX-2 inhibitors will strengthen the vaccine response 
to H56, and that the two together will shorten the duration of chemotherapy for multidrug-resistant TB. This 
initial study is recruiting participants in Oslo, Norway and is supported by the Norwegian Research Council.84 
Despite these interesting applications of H56 during and after TB drug therapy, the SSI has indicated that future 
development efforts will focus on prevention-of-infection trials rather than prevention-of-recurrence trials.85 
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Other Approaches and Developments
The TB vaccine field’s only ongoing phase IIb efficacy trial is evaluating whether two intramuscular doses of 
M72 + AS01, a subunit vaccine developed by GlaxoSmithKline (GSK) that pairs MTB antigens 32A and 29A 
with GSK’s AS01 adjuvant, protects MTB-infected, HIV-negative adults from TB disease progression compared 
with placebo.86 The trial, which opened in 2014 and is being conducted in South Africa, Kenya, and Zambia, 
reached its targeted enrollment of 3,500 participants in 2015 and is now in follow-up for the primary 
outcome analysis, which will be case driven. The analysis will be conducted after investigators detect 21 cases 
of pulmonary TB; results are expected in late 2018.87 
Activity also continues on the development of two vaccines designed to replace BCG and be administered 
to infants soon after birth: VPM1002 and MTBVAC. VPM1002, a live, recombinant form of BCG developed 
by Vakzine Projekt Management in Germany and licensed to the Serum Institute of India (SII), recently began 
a phase IIa trial in over 400 South African newborns. The study will compare the safety and immunogenicity 
of VPM1002 versus BCG in both HIV-exposed and unexposed infants.88 The SII is currently in discussions 
with regulatory authorities in India to take VPM1002 into two larger studies: a phase IIb BCG-replacement 
trial in newborns (pending a favorable outcome from the South African study), and a phase III prevention-of-
recurrence trial in adults.89 Work also continues on MTBVAC, a live, genetically attenuated form of MTB that 
was made less virulent by the deletion of two genes (phoP and fadD26). A phase IIa safety, dose-escalation, 
and immunogenicity study of MTBVAC in South Africa is currently recruiting participants in two phases. The 
first will randomize MTB-negative, BCG-vaccinated adults to receive either MTBVAC or BCG. If safety is 
demonstrated in this group, the trial will progress to the second stage and randomize infants to receive either 
BCG or MTBVAC at one of three doses.90 A phase IIa study among South African adults is also planned.91 
Efforts to replace BCG will likely receive less financial and intellectual attention in the coming years. In 
contrast with earlier phase IIa and IIb trials, many of which were conducted in either adults with HIV or 
infants,92,93 vaccine developers are now focusing on HIV-negative adolescents and adults, who account for the 
majority of MTB transmission globally. (This may be one reason why VPM1002 and MTBVAC—each designed 
as BCG-replacement vaccines—are also being tested in adult prevention-of-recurrence and prevention-of-
infection trials). By conducting fewer clinical trials in children and people with HIV, TB vaccine developers 
are effectively making the decision to direct research away from the two groups most vulnerable to TB. If 
focusing testing on adults without comorbidities shortens the clinical development timeline, and if the resulting 
vaccine averts cases of TB in children and people with HIV through a herd immunity effect by interrupting 
TB transmission among the adult contacts around them (as modeling suggests could occur),94 then this may 
prove to be a prescient move. But that string of assumptions contains many uncertainties, and developers 
should acknowledge that the current strategy risks leaving behind two key TB-affected populations with greatly 
enhanced risks of disease and death that rightly draw significant attention from global health actors. 
 
PROGRESS IN TB PREVENTIVE THERAPY DEVELOPMENT 
Although they are no longer the focus of TB vaccine development, children and people with HIV still 
occupy the center of efforts to develop new or improved TB preventive therapies (see table 2). Research 
into preventive TB treatment is pursuing answers to two primary questions. First, what are the most effective 
regimens for treating MTB infection, particularly in high-risk groups, including children, people with HIV, and 
pregnant women? And second, how should physicians treat probable infection with drug-resistant TB (DR-TB)? 
As with the overall TB drug pipeline (see “Tuberculosis Treatment Pipeline,” page 35, for a detailed overview), 
there are few new drug candidates available for investigators to study. Consequently, much of the activity has 
focused on optimizing existing drugs for TB prevention (e.g., rifapentine, a rifamycin that is closely related 
to rifampin and is off-patent and marketed by the French pharmaceutical company Sanofi) or studying the 
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chemoprophylactic potential of new drugs (e.g., delamanid, a nitroimidazole developed by the Japanese 
company Otsuka and approved for the treatment of DR-TB). Despite the limited armamentarium, the field is 
poised to make major strides in coming years with planned or ongoing phase III trials that, if successful, could 
dramatically refashion treatment guidelines.  
Table 2. Clinical Trials to Prevent Tuberculosis Disease
Study/Regimen Status Population Sponsor(s)
A5279 
Self-administered daily rifapentine + isoniazid 
for 1 month (vs. isoniazid daily for 9 months)
NCT01404312*
Fully enrolled People with HIV either living in high-TB prevalence 




6 months daily delamanid (vs. isoniazid)
Beginning enrollment 
Q4 2016
High-risk (HIV+, TST/IGRA+, or <5 years old) 
household contacts (adults, adolescents, and 
children 0–5 years old) of individuals with MDR-TB
ACTG, IMPAACT
WHIPP TB
6H versus 3HP (given once) versus p3HP 
(given once a year for two years)
Beginning enrollment 
Q3 2016




6 weeks of daily rifapentine (P) versus 
rifamycin-based standard of care regimens 
(3HP, 4R, 3HR)
Protocol development Household contacts, people with HIV, individuals 
with recent TST or IGRA conversion
TBTC, TBESC, UK MRC, 
University College 
London
4R versus 9H 
4 months daily rifampin (self-administered)
NCT00931736*
Fully enrolled Adults with positive skin test or QuantiFERON-TB 
blood test, including people with HIV who are not 
on ARVs whose efficacy is reduced by rifampin
McGill University, CIHR
V-QUIN 
6 months daily levofloxacin (vs. placebo)
ACTRN12616000215426**
Protocol development Household contacts (adults, adolescents, and 
children ≥3 kg) of individuals with MDR-TB
NHMRC, VNTP
P2001 
12 weeks of supervised 3HP
NCT02651259*
Protocol development HIV-positive and HIV-negative pregnant and 
postpartum women with MTB infection
IMPAACT
CORTIS





HIV-negative adults with MTB infection in high-risk 
individuals identified by a gene-based signature 
of risk
University of Cape 
Town, Bill & Melinda 
Gates Foundation
* Clinicaltrials.gov identifier; for more details, see http://www.clinicaltrials.gov
** Australian New Zealand Clinical Trials Registry identifier; for more details, see http://www.anzctr.org.au
 ACTG: AIDS Clinical Trials Group, U.S. National Institute of Allergy and
   Infectious Diseases (NIAID)
ARVs: antiretrovirals
CIHR: Canadian Institutes of Health Research
IGRA: interferon gamma release assay (QuantiFERON-TB Gold In-Tube 
   (QFT) or T-SPOT TB test)
IMPAACT: International Maternal Pediatric Adolescent AIDS Clinical Trials
   Group, NIAID
NHMRC: National Health and Medical Research Council (Australia)
NIAID: National Institute of Allergy and Infectious Diseases (U.S.)
TBESC: Tuberculosis Epidemiologic Studies Consortium, U.S. Centers for
   Disease Control and Prevention
TBTC: Tuberculosis Trials Consortium, U.S. Centers for Disease Control and
   Prevention
UK MRC: Medical Research Council, United Kingdom
VNTP: Vietnam National Treatment Program 
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Treating MTB Infection in Household Contacts of People with DR-TB
The question of how to treat MTB infection among individuals exposed to DR-TB is one of the most vexing, 
and least studied, in TB prevention. To date, no randomized controlled trials have been conducted to guide 
prophylactic treatment of people exposed to DR-TB, who are often people living in the same household 
as someone with multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB). For household 
contacts of DR-TB patients, MTB infection is an experience fraught with uncertainty, as progression to active 
disease could entail an MDR-TB or XDR-TB diagnosis. The lack of research on this topic has resulted in wildly 
divergent guidelines. On one end of the spectrum, the U.S. Centers for Disease Control and Prevention 
(CDC) outlines a range of treatment options—typically 6–12 months in duration—based on the idea that 
physicians should treat probable DR-TB infection with two or more drugs to which the infecting organism is 
believed susceptible.95 On the other end, the WHO contends “strict clinical observation and close monitoring 
for the development of active TB disease for at least two years is preferred over the provision of preventive 
treatment.”96
To help fill this evidence gap, the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric 
Adolescent AIDS Clinical Trials Network (IMPAACT) are collaborating on the PHOENIx study, which will enroll 
HIV-infected and uninfected child, adolescent, and adult household contacts of adults newly diagnosed 
with MDR-TB, pre-XDR-TB, and XDR-TB.97 Since being described in last year’s Pipeline Report, the study has 
undergone an important modification to the composition of the experimental arm and will now compare the 
safety and efficacy of delamanid, rather than levofloxacin, to isoniazid—each given daily for six months—for 
preventing active TB among individuals exposed to DR-TB. Eligible household contacts include people with 
HIV of any age, children ages 0–5, and anyone older than 5 years who reacts positively to TST or IGRA.98 
Delamanid has several qualities that make it an attractive potential treatment for probable DR-TB infection. 
Most importantly, it is effective at treating DR-TB, at least according to the phase IIb data that underpinned 
its approval by the European Medicines Agency in 2015.99 It also appears to be generally safe and well 
tolerated; has few drug-drug interactions with antiretrovirals that might limit its use among people with 
HIV; can be given as a single daily dose (thereby promoting adherence); and can be administered safely to 
children (a safety study of delamanid in children at all age groups is nearing completion).100,101 
Given that PHOENIx is the first large MDR-TB household study undertaken by ACTG and IMPAACT, the two 
networks have been conducting an observational feasibility study to prepare for the larger trial. Clinical trial 
sites participating in this preparatory study hit the targeted enrollment of 300 adult MDR-TB index cases and 
over 800 household contacts much faster than investigators had anticipated, suggesting that TB prevention 
trials among DR-TB patients and their close contacts are feasible despite a lack of experience in this area.102 
In addition to PHOENIx, two other randomized controlled trials are investigating approaches to treating 
probable DR-TB infection. In Vietnam, the V-QUIN study is testing six months of treatment with levofloxacin 
versus placebo in Vietnamese adult, adolescent, and child household contacts of MDR-TB patients.103 In South 
Africa, the TB CHAMP study will compare levofloxacin versus placebo in children ages five years and younger 
(see “Pediatric Tuberculosis Treatment Pipeline,” page 52, for a detailed discussion of pediatric TB drug 
research).
 
Treating MTB Infection in People with HIV
Work to develop better TB prevention options for people with HIV is also progressing, and most of this work is 
revolving around rifapentine. The notion of using rifapentine to prevent TB has amassed considerable interest 
in the wake of the landmark phase III trial by the Tuberculosis Trials Consortium (TBTC), which demonstrated 
the safety and efficacy of 12 once-weekly doses of rifapentine and isoniazid (the 3HP regimen).104 However, 
most participants in this trial were HIV-negative, raising questions about the effectiveness of the 3HP regimen 
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in people with HIV. The TBTC recently published the results of a 403-person substudy conducted with the 
ACTG and IMPAACT under the larger trial that showed 3HP is as safe and effective at preventing TB among 
people with HIV as nine months of daily isoniazid (9H) and is better tolerated.105 These findings complement a 
study among nearly 1,150 adults with HIV and MTB infection in Soweto, South Africa, in which 3HP treatment 
had similar (although not superior) efficacy in preventing TB disease, fewer side effects, and better treatment 
completion rates than six months of isoniazid treatment.106
New research is investigating whether administering multiple courses of 3HP over several years offers people 
with HIV more durable and long-lasting protection against TB compared with a single round of 3HP in high-
TB-burden countries. (Previous Pipeline Reports have summarized related work investigating the durability 
of daily isoniazid preventive therapy, or IPT). The proposed Weekly High-dose Isoniazid and Rifapentine 
[P] to Protect against TB (WHIPP TB) study will investigate this question using a two-part approach.107 Part 
A is an observational, randomized comparison of 3HP versus six months of daily isoniazid (6H) treatment 
among people with HIV. The primary objective is to compare treatment completion between the two 
regimens; secondary objectives will compare 3HP to 6H with respect to TB incidence, all-cause mortality, and 
discontinuation of therapy as a result of adverse events.108 If 3HP performs favorably in part A, the results 
could lead the WHO to recommend the provision of 3HP to prevent TB among people with HIV in TB and 
HIV high-burden countries, offering an alternative to IPT. Part B is a randomized, controlled trial with three 
arms and will enroll concurrently to part A. Participants in the first arm will receive one course of 6H; those 
in the second will receive one round of 3HP; and those in the third will receive two rounds of 3HP, one given 
each year for two years (referred to as pulsing 3HP, or p3HP). The trial will enroll 4,000 participants at 12–14 
sites in Ethiopia, Malawi, South Africa, and Mozambique. After two years of follow-up, the primary outcome 
analysis will compare the effectiveness of a single round of 3HP versus p3HP in preventing TB disease among 
people with HIV.109 The study is sponsored by the KNCV Tuberculosis Foundation and funded by the U.S. 
Agency for International Development (USAID); Sanofi is donating drugs for the study. Investigators have 
received ethics approval and are awaiting final regulatory go-ahead from the South African Medicines Control 
Council. They expect to begin enrollment in June 2016.110 
The ACTG is also investigating the potential of daily rifapentine and isoniazid (HP) to prevent TB in people 
with HIV in study A5279. This phase III clinical trial is comparing the effectiveness of daily HP given for 4 
weeks to daily isoniazid given for 36 weeks (9H) among 3,000 people with HIV 13 years of age and older 
who either have MTB infection or live in high-transmission areas. The study reached its targeted enrollment 
at the end of 2014 and will complete follow-up in November 2017.111 Building on this effort, the TBTC, 
together with the U.S. CDC’s Tuberculosis Epidemiological Studies Consortium (TBESC), the U.K. Medical 
Research Council (MRC), and University College London (UCL), is developing a study of daily rifapentine in 
settings of low-to-medium TB incidence. The study is still in the early stages of protocol development, but the 
current plan is to study the safety, tolerability, and efficacy of six weeks of daily rifapentine (P), primarily among 
HIV-negative individuals.112 As written, the control arm in the study will be a composite of the three rifamycin-
based standard-of-care regimens included in the WHO Guidelines on the Management of Latent Tuberculosis 
Infection: 3HP, three months of daily rifampin plus isoniazid (3HR), or four months of daily rifampin (4R).
The considerable potential of rifapentine to improve TB preventive therapy can only be unlocked if the drug 
becomes more widely available. Currently, rifapentine is approved for the treatment of MTB infection in just 
a single country, the United States, despite being studied through a series of public-private partnerships in at 
least a dozen more.113 Sanofi has made some progress over the past year in broadening access to rifapentine, 
most notably through its decision to list rifapentine in the catalogue of the Global Drug Facility (GDF).114 
This means that, for the first time, TB programs outside of the U.S. will have a direct route for purchasing 
rifapentine and may even be able to start using the drug while registration is pending by exercising import 
waivers and other pre-approval access mechanisms.115 Sanofi has also taken steps to register rifapentine in a 
wide swath of countries, with the most progress seen in East Asia (Taiwan and Hong Kong).116 Still, access to 
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rifapentine remains far too constrained given its central role in the TB prevention research agenda. For their 
part, investigators should be asking more of Sanofi in terms of securing commitments to making rifapentine 
available swiftly and without undue delay after the conclusion of efficacy trials. This is all the more justifiable 
considering that the lion’s share of investment in rifapentine has come from the public sector. In the United 
States alone, three public agencies (CDC, NIH, and USAID) are footing the bill for trials that may expand the 
use of rifapentine to a broader array of countries and patient populations.  
 
PROGRESS IN PUBLIC ENGAGEMENT IN TB PREVENTION RESEARCH
The strategies being pursued by developers of TB vaccines and preventive therapies carry a mixture of risk and 
reward. For clinical trial participants, the decision about whether to enroll in a study involves a more personal 
risk/benefit calculus. Progress in the clinical research efforts described above will depend on the willingness 
of people at risk of TB to participate in experiments with uncertain outcomes. A similar bargain is struck by 
preventive interventions given that, as the writer Eula Biss reminds us, “it is through us, literally through our 
bodies, that certain public health measures are enacted.”117 For prevention, especially, it is important that 
these measures be safe, effective, and acceptable for the healthy individuals who will be asked to take therapy 
or undergo vaccination to ward off an event whose occurrence is probabilistic and may never come to pass. 
Cutting-edge science alone is not enough to guarantee that new TB prevention methods will be acceptable 
to their intended users—a group that at its largest could include all 2 billion people estimated to be infected 
with MTB globally. TB prevention science must progress in lockstep with the meaningful engagement of the 
communities that will be asked to embrace any resulting new technologies and that will be called, time and 
again, to participate in the research to develop them. 
Thoughtful community engagement is an important element of any TB R&D endeavor, but its presence or 
absence invokes unique considerations for prevention research. The science underlying prevention carries 
profound implications, not only for its potential to avert suffering resulting from disease, but also for its ability 
to reshape how individuals imagine themselves as either sick or healthy in relation to new conceptions of risk 
and susceptibility.118 If validated in clinical trials, correlates of risk, such as the gene signature identified from 
the South African adolescent cohort study, could create whole new clinical categories of people—the pre-
symptomatically ill—that are subject to interventions ranging from treatment to vaccination to repeat testing. 
It is unclear whether signatures of risk will end up expanding the proportion of people with MTB infection in 
need of intervention, or whether they will narrow the eligibility for TB preventive services by assigning MTB-
infected individuals to a spectrum of risk with interventions reserved for those at the high end. In either case, 
TB prevention science promises to open many people who consider themselves healthy to new forms of 
medical action. Engaging communities in TB prevention research, from the laboratory to the clinic, will help to 
ensure that the development of new TB vaccines and preventive therapies moves forward in parallel with the 
knowledge, values, concerns, and needs of the communities around the world at risk for TB.  
Given these potentially transformative considerations, moves by Aeras in the last year to form a community 
engagement program come not a moment too soon. As designed, the program contains many of the best 
practices developed by earlier community engagement initiatives supported by TB drug developers such as 
the TB Alliance and the TBTC. Community engagement in TB vaccine trials sponsored by Aeras will occur on 
multiple levels: individual trial sites (e.g., through local initiatives led by community advisory boards), sponsors 
(e.g., through community reviews of clinical trials protocols), and regional (e.g., through the formation of an 
Africa TB vaccine advocates network).119 Among the proposed activities, the most important is Aeras’s plan 
to involve community representatives in reviewing clinical trials protocols—a key step for building scientific 
literacy and for incorporating community feedback into the research agenda. Funders of TB vaccine R&D 
should commit to funding the Aeras community engagement program and acknowledge this work as the 





For funders: Ensure financing mechanisms are sufficiently flexible and durable to support the 
multi-year, collaborative research endeavors that will be required to make progress against a 
challenge as complex and intractable as MTB infection. 
For example, nearly ten years passed between when the South African adolescent cohort enrolled its first 
participant in 2005 and when it published results announcing the discovery of a risk signature of disease 
progression in the Lancet in 2016. This was not time wasted, and the cohort will likely yield publications 
and results for years to come. Further advancing our knowledge of MTB infection and TB disease may 
require larger cohorts with even longer periods of follow-up. In addition, funding agencies should support 
translational work to bridge advancements in basic science with clinical development and maintain openness 
to a wide range of approaches that probe the nature of MTB infection from the perspective of both host and 
pathogen, and through the application of new assays and imaging technologies in both humans and animal 
models. 
 
For vaccine researchers and developers: Continue to explore a greater diversity of approaches 
to TB vaccine development through the use of experimental medicine studies and trials designed 
around novel endpoints. 
Ultimately, this will likely require developers to introduce wholly new vaccine candidates whose designs look 
beyond the narrow focus on cell-mediated immunity that has dominated past efforts. The development and 
introduction of new assays that are able to translate signals of immunogenicity between lung and blood (or 
capable of safely measuring vaccine responses directly in the lung itself) should also be a priority. Developers 
and their sponsors should not foreclose on clinical trials among infants and people with HIV, two of the 
groups most in need of a new TB vaccine. Although previous trials in these two populations have fallen short 
of expectations, there is much that can be learned from past failures. Rather than wholly abandon vaccine 
concepts and constructs that did not work, vaccine researchers and developers should more forthrightly 
interrogate the reasons behind disappointing results. 
 
For drug researchers and developers: Accelerate research to understand MTB persistence and 
the nature of latency to develop new drugs targeting latent infection. 
Efforts to understand MTB persistence would benefit from initiating a dialogue with researchers involved in 
vaccine development about differences in how the TB drug and vaccine fields approach preclinical testing. 
Each field is confronting challenges related to MTB persistence and the nature of latency, but vaccine and 
drug developers do not always measure the same pathology or immunological events using relatable 
endpoints or definitions of scale in the animal models in which much of this work will be conducted. Closer 
collaboration with their vaccine counterparts might also open the door for drug developers to use vaccines 
as adjuncts to shorten therapy or reduce the risk of relapse. In the meantime, ongoing efforts to shorten 
and simplify TB preventive therapy for children, people with HIV, pregnant women, and household contacts 
of people with DR-TB should continue. The advanced stage of many of TB prevention trials obligates 
pharmaceutical companies involved in this research—namely, Sanofi and Otsuka—to take steps to register 




For all researchers and developers: Recognize community engagement in research as the 
ethical complement to good clinical practice and take steps to involve representatives from TB-
affected communities in all stages of R&D. 
The potential of ongoing or planned TB preventive therapy and vaccine studies to refashion clinical practice in 
ways that could render many more people with asymptomatic MTB infection eligible for medical intervention 
makes it imperative that developers create meaningful spaces for community voices, concerns, and priorities 
to enter the research process. Communities must become true partners in TB prevention research, and not 
merely its silent beneficiaries.  
For activists: Take up TB prevention as a unified cause and break with the habit of advocating for 
vaccines, preventive therapy, and infection control as separate and unrelated technological fixes. 
With the exception of TB PROOF—a South African advocacy group founded by doctors who contracted TB 
that is dedicated to preventing MTB infection among healthcare workers—activist voices in TB prevention 
have been few in number and modest in volume. This absence does not reflect a lack of need. A global 
shortage of BCG continues into its third year, needlessly endangering the lives of millions of infants.120 
Rifapentine, the cornerstone of TB preventive therapy research, is registered for the treatment of MTB infection 
in just one country, despite being studied in at least a dozen more. Individuals exposed to MDR-TB have few 
evidence-based options to treat probable drug-resistant infection. And countries remain slow to rollout proven 
interventions such as IPT to people with HIV, 400,000 of whom died from TB in 2014.121 We are one year 
closer to 2025, the year WHO says new prevention tools must be introduced to reach the End TB Strategy’s 
goal of eliminating TB by 2035, and there is no new vaccine or transformative preventive drug regimen on the 
immediate horizon. The clock is ticking. 
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The Tuberculosis Treatment Pipeline:  




In the past year, the development of new tuberculosis (TB) drug candidates experienced some 
setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a 
phase III combination trial that includes the new drug pretomanid), the discontinuation of candidate 
TBA-354 (due to signs of toxicity), and the official end of development of AZD5847 (due to lack of 
anti-TB activity). In a bright spot, Qurient’s Q203 entered phase I, representing a new drug class 
and a new sponsor in TB clinical trials. But overall, the new TB drug development landscape remains 
parched, with just five candidates from four classes in development—including bedaquiline and 
delamanid, which already have conditional marketing approval in some countries. Most of these 
drugs have been stalled for years. Delays across the board, from sponsors, from regulators, and 
from funders, are preventing nascent progress from flourishing. The phase III trial for bedaquiline has 
finally started enrolling—some five years after the phase IIb trial concluded. Sutezolid is still awaiting 
entry into phase IIb, nearly five years after showing promise in phase IIa. Delamanid’s phase III trial 
is chugging along dutifully, but, due to the lengthy standard-of-care background treatment and 
follow-up time required in TB clinical studies, won’t give results till 2018. 
More activity is ongoing among trials testing combinations of drugs already on the market, often 
called repurposed drugs. But again, most will not bear fruit for several years. These various trials to 
optimize therapies point to creativity among researchers but also to the poor existing evidence base 
for use that has left the TB field reliant upon lengthy, poorly tolerated—and, for drug-resistant TB, 
marginally effective—regimens. Some exciting advances are being made in preventive therapy for 
TB—these are now reported in the TB prevention chapter (see page 15)—but this chapter will focus 
exclusively on the development of treatments for active TB disease. 
New guidelines from the World Health Organization (WHO) may help improve the treatment 
of multidrug-resistant TB (MDR-TB) by updating options for stronger treatments in combination 
regimens, though the newly recommended putative treatment-shortening approach has yet to be 
validated in randomized controlled trials. However, the updated WHO guidelines will help increase 
the use and availability of drugs of greater potency such as delamanid, bedaquiline, clofazimine, 
and linezolid.1 MDR-TB treatment is still inadequate, with fewer than 10% of those with the disease 
successfully treated worldwide, and less than 2% of those who may benefit from new drugs receiving 
them.2,3 Investment in new alternatives is also scandalously low; in 2014, just US$243 million out of 
the needed US$740 million were available for TB drug research and development (R&D).4 Recent 
global and national strategic plans to address antimicrobial resistance and TB, such as those from 
the Netherlands, the United States, and the United Kingdom, must go beyond lip service and be met 
with financial commitments to increase support for TB R&D.5,6,7,8 Countries with high TB burdens and 
large economies, such as Brazil, China, India, Indonesia, Russia, and South Africa, must contribute 
far more to R&D as well as to service scale-up.




UPDATES ON NEW COMPOUNDS IN DEVELOPMENT
 
Table 1. Drugs in Development for Tuberculosis 
Drug Class Sponsor(s) Phase
bedaquiline diarylquinoline Janssen (Johnson & Johnson), TB Alliance, NIAID, SAMRC, the Union, UNITAID, USAID III
delamanid nitroimidazole Otsuka, NIAID, UNITAID III
pretomanid nitroimidazole TB Alliance III
sutezolid oxazolidinone Sequella, NIAID IIa
Q203 imidazopyridine Qurient, Infectex I
NIAID: National Institute of Allergy and Infectious Diseases (United States)  
SAMRC: South African Medical Research Council  
The Union: International Union Against Tuberculosis and Lung Disease 
USAID: The U.S. Agency for International Development
 
Q203
A new compound, Q203, developed by Qurient, entered clinical testing in late 2015.9 Q203’s phase I, 
single-dose, dose-escalating study has completed enrollment. Results will be shared in 2017, and phase II 
trials will likely start then.10 A member of the imidazopyridine class, Q203 targets the respiratory cytochrome 
bc1 complex, inhibiting the synthesis and homeostasis of adenosine triphosphate (ATP), thereby crippling the 
energy conversion system in both replicating and nonreplicating TB bacteria.11 Q203 brings much-needed 
diversity to the pipeline and is an important addition to early-stage development as TBA-354 drops out of the 
running. Qurient is developing Q203 with support from the Korea Drug Development Fund and is partnering 
with Infectex to develop the drug for Russia and the other Commonwealth of Independent States (CIS) markets.
 
TBA-354
TBA-354, in the same class of drugs as delamanid and pretomanid (the nitroimidazole class), was the first 
candidate to enter phase I TB trials in six years, but regrettably, this rising star burned out quickly. After a 
phase I dose-escalating trial showed an association with mild signs of neurotoxicity (repetitive uncontrolled 
eye movements and overactive reflexes, from which all affected study participants recovered), the TB 
Alliance voluntarily placed TBA-354 on hold in January 2016 and announced the discontinuation of its 
development in March 2016.12,13 This unfortunate event nonetheless represents responsible stewardship 
and communication of results, and it reinforces the need for more investment in TB R&D since—as in all 
disease areas—the majority of early-stage drug candidates will fail, necessitating a variety of compounds in 
development at a given time. 
 
Pretomanid
The development of another nitroimidazole, pretomanid, has also been hampered—this time by unexpected 
fatalities that led to a partial clinical hold on pretomanid and a complete hold for the STAND study.14 This 
phase III trial was testing the combination of pretomanid (at different doses) along with moxifloxacin and 
pyrazinamide (PaMZ) in people with drug-sensitive TB (DS-TB) and some forms of MDR-TB; TAG has previously 
critiqued the design of this trial, particularly its uncontrolled MDR-TB arm and the regimen’s expected 
vulnerability to resistance.15 Unfortunately, the experimental regimen was associated with high levels of liver 
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toxicity, which caused the death of three participants, all in the drug-sensitive PaMZ arms of the study. The 
study’s Data Safety Monitoring Committee (DSMC) promptly recommended a suspension in enrollment in 
September 2015 and, after further analysis, in November 2015 recommended restart of enrollment with the 
addition of safety procedures and, at least initially, the exclusion of people with HIV.16 In May 2016, the DSMC 
completed its review and concluded that full enrollment could resume regardless of HIV status; in May 2016, 
the Alliance noted it was preparing all necessary regulatory submissions to prepare for resuming enrollment 
into the STAND trial.17
The NiX-TB trial, which is testing pretomanid, bedaquiline, and linezolid in participants with extensively drug-
resistant TB (XDR-TB), is faring better—though there is no randomization or control arm in this open-label 
study. As of March 2016, 37 patients were enrolled, and 14 patients completed treatment. The TB Alliance 
reports—though data have not yet been peer reviewed or formally presented at a scientific meeting—that four 
patients have died early on in treatment due to underlying disease, and that all other patients are doing well 
and showing good clinical response, with the majority having converted their sputum cultures to negative in 
the first two months of treatment. Linezolid toxicity has been manageable, though some dose interruptions and 
dose reductions occurred, mainly after week 9. The first formal interim analysis will occur in the third quarter 
of 2016.18
NC-005, a phase IIb trial that is testing the efficacy and safety of two months of bedaquiline (in a simpler 
dosing scheme than the currently recommended one), pretomanid, and pyrazinamide in about 240 patients 
with either DS- or MDR-TB, completed enrollment at the end of 2015 and will have results at the end of 
2016.19 The PRACTECAL study, a multiarm, open-label, randomized controlled pragmatic trial from Médecins 
Sans Frontières (MSF) that will examine various combinations of pretomanid, bedaquiline, moxifloxacin, 
linezolid, and clofazimine given for six months to people with MDR-TB in comparison to the WHO standard of 




Readers will be dismayed to learn that sutezolid, an oxazolidinone hoped to be a safer alternative to linezolid, 
is still stuck in phase IIa some three years after Pfizer ended its anti-infectives program and licensed the 
promising candidate to the small pharmaceutical company Sequella. Sequella has recently called sutezolid a 
“companion drug” for its probably ineffective compound, SQ109.21 Sutezolid is, in fact, a candidate in high 
demand on its own (unlike SQ109, see more in box “Foul Play in the Federation,” page 41). Fortunately, the 
U.S. National Institutes of Health (NIH) will sponsor the manufacture of 15,000 doses of a 600 mg tablet, 
which should be ready within six months after a protocol for an AIDS Clinical Trials Group (ACTG) study is 
given the green light. ACTG study A5289 is under development and currently features sutezolid replacing 
ethambutol in the experimental arm of a two-stage, adaptive study design to evaluate the pharmacokinetics, 
safety, and initial efficacy of sutezolid over two and eight weeks in people with DS-TB. It would determine 
an ideal dose for sutezolid, as well as evaluate interactions between rifamycins and sutezolid and its main 
metabolite. 
If the study is approved for implementation, A5289 will trigger sutezolid’s long-awaited entry into phase IIb.22 
Sequella and Johns Hopkins (which owns the intellectual property rights for the development of sutezolid in 
combinations) should turn over intellectual property rights, and Sequella should also release the toxicity and 
clinical data on sutezolid to date to the Medicines Patent Pool (MPP). Fortunately, it appears Johns Hopkins 
has entered into negotiations to do so.23 If Sequella refuses to turn over early data to facilitate collaboration, 
it will take other interested parties three to five years and several million dollars to reproduce data to move 
forward with development—wasted time and money that are simply not available given the scarce resources 




Bedaquiline’s use in programmatic settings is on the rise (see table 2), and data described below support the 
continued expansion of its use. Indeed, the new WHO MDR-TB guidelines better categorize bedaquiline (and 
delamanid) as agents that can be added on to an MDR-TB regimen to ensure incorporation of five effective 
drugs.24
Data from South Africa’s incorporation of bedaquiline first into a clinical access program and then into 
routine programmatic use indicate the drug’s safety, effectiveness, and importance in treating MDR-TB. 
The bedaquiline clinical access program, which started with just five sites while the Medicines Control 
Council (MCC) was reviewing bedaquiline’s dossier for marketing approval, enrolled 221 patients for 
whom other treatment options had been exhausted. Data from the full cohort of 221 patients with follow-up 
will be available in 2017, but an interim analysis of the 91 patients with MDR- or XDR-TB enrolled by July 
2014 (60 of whom had completed treatment) showed that 70 percent had culture converted or remained 
culture negative—an impressive result for these patients with intractable forms of TB, many of whom had 
HIV infection and low CD4 counts (as opposed to carefully screened clinical trial participants, who are 
generally healthier and have fewer complications). The South African experience showed that participants 
with HIV on appropriate antiretroviral therapy (ART) did quite well on bedaquiline, and participants could 
easily be switched to nevirapine- or lopinavir/ritonavir-based regimens for the duration of their treatment 
with bedaquiline and then be placed back on the preferred efavirenz-based fixed-dose ART (whose use is 
contraindicated with bedaquiline due to drug-drug interactions).25 Notably, lopinavir/ritonavir does increase 
bedaquiline exposure compared with no ART (median area under the curve 67, 002 vs. 34, 730 ng · h/mL,  
P  = .003; median time of highest concentration [Tmax] of 6 vs. 4 hours, P  =  .003; and terminal half-life of 55 
vs. 31 hours P  = .004), though clinical implications are unknown.26
Based on this positive experience, and with the MCC’s approval of bedaquiline, the South African Department 
of Health launched a framework for routine programmatic use of bedaquiline in June 2015.27 Under this 
framework, bedaquiline can be used in the public sector without review by the national or provincial program 
in anyone 18 years or older with pre-XDR-TB (TB that is resistant to either a fluoroquinolone or an injectable, 
as well as isoniazid and rifampin) or XDR-TB, whose TB shows InhA and KatG mutations (indicating resistance 
to isoniazid), who has intolerance to second-line drugs (such as drug-induced hearing loss or psychosis), 
or who has a history of surgery, as long as he or she has no personal or family history of QT prolongation 
(a potentially dangerous disturbance in the heart’s electrical activity, for which bedaquiline increases the 
risk). The South African treatment program does allow for people who are under 18, who are pregnant, or 
who have MDR-TB treatment failure without proven second-line drug resistance to receive bedaquiline per 
individual case review and approval.
Over 1,000 patients from all but one (Mpumalanga) of South Africa’s provinces have now received 
bedaquiline. The vast majority have XDR-TB (39%) or pre-XDR-TB (40%); 12% received bedaquiline due 
to intolerance of other drugs, 8% due to InhA and KatG mutations, and 1% because they were surgical 
candidates. For the first time, a new TB drug has been added to routine management for MDR-TB, and it is 
going very well.28,29 In a separate analysis of the 598 patients who started bedaquiline between March and 
end of September 2015, the most common reason for denying bedaquiline initiation was having too few 
potentially effective drugs in the proposed background regimen, pointing to the urgent need for companion 
drugs such as linezolid and delamanid. Indeed, provinces that quickly scaled up bedaquiline use were those 
that had linezolid access, as well as those that had tools to detect need for bedaquiline (genotypic second-line 
drug resistance testing and capacity to detect high-frequency hearing loss).30
More data to inform the optimal use of bedaquiline come from a French cohort of patients started on 
bedaquiline between 2011 and 2013. In this cohort of 45 patients, 33 patients received bedaquiline for 
longer than six months (the duration that was studied in phase IIb clinical trials and hence the recommended 
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duration of treatment under conditional approvals and in WHO guidance);31 some patients received 
bedaquiline for up to 768 days, with a median of 360 days. Patients receiving courses of bedaquiline for 
more than six months were more likely to have hepatitis C (58% vs. 17%, P = .020), to have been previously 
treated for TB (94% vs. 25%, P < .001), and to have sputum culture-positive TB (97% vs. 75%, P = .048). 
In those who received a standard six-month course of bedaquiline, 75% achieved cure, versus 82% of those 
receiving a longer course. There were no significant differences in adverse events in the two groups. These 
findings indicate that prolonged bedaquiline use is well tolerated, at least in this small cohort, and that good 
outcomes may be partially explained by the decision to extend bedaquiline treatment in select challenging 
cases. The clinicians from the French program therefore recommend extension of bedaquiline in cases that 
would have fewer than four effective drugs if bedaquiline were stopped, that have delayed microbiological 
response (i.e., culture positivity after four months of treatment), and risk factors for poor outcomes (e.g., 
extensive lung disease, low body mass index, high acid-fast bacilli [AFB] positivity, or HIV), as long as 
prerequisites such as pharmacovigilance, close monitoring, patient consent, treatment tolerability, and expert 
opinion are in place. 
All countries with MDR-TB burdens should follow France’s and South Africa’s examples and safely incorporate 
bedaquiline into their treatment programs. Ministries of health in countries such as India and the Philippines 
have been negligent in making this drug available to their citizens who so desperately need it: despite 
registration and availability of the drug and guidelines for its use in country, as of May 31, 2016, neither has 
started a single patient on treatment under routine programmatic conditions. 
Indeed, further research supports the increased use of bedaquiline. A new analysis of the phase II, 
randomized, double-blind C208 stage 2 study of bedaquiline showed that only two out of ten participants 
receiving bedaquiline who had either converted or relapsed acquired resistance to companion drugs, versus 
16 out of 30 in the background regimen plus placebo arm. No participant developed pre-XDR-TB or XDR-TB 
in the bedaquiline arm, versus six and two participants, respectively, in the placebo arm. Though the number 
of participants in this analysis is very small, these data point to bedaquiline’s potential ability to protect against 
the amplification of resistance to other drugs. Notably, one out of ten participants in the bedaquiline arm 
showed a greater than fourfold increase in the minimum inhibitory concentration of bedaquiline, indicating 
potential acquired resistance to the new drug, though this does not necessarily correlate with clinically 
observed lack of drug efficacy.32 Some clinical cases of resistance to bedaquiline have been reported.33
A recent analysis of C209, the phase II single-arm open-label trial of bedaquiline plus background regimen 
in 233 adults with MDR-TB (including XDR-TB and pre-XDR-TB), showed high rates of culture conversion and 
good outcomes with bedaquiline, regardless of type of MDR-TB. Of 205 participants included in the modified 
intention to treat analysis, 40% had pre-XDR-TB or XDR-TB, and 66% had extensive cavitation. Yet outcomes 
were still good: using a conservative measure of cure (the old WHO definition of five consecutive negative 
cultures), 61% of participants were cured, and only 16% failed, 7 percent died, and 15% transferred out or 
were lost to follow-up at 120 weeks after treatment initiation. Of 37 patients with XDR-TB, 23 (62%) culture 
converted, and all remained culture negative during the trial—though follow-up data were only available 
for 16 of 23 participants for a median of 5.4 months. In multivariate analysis, cure was associated with 
newly diagnosed MDR-TB (82% versus 71% cured in previously treated participants, P < .05), and with lower 
AFB score (90% of sputum smear-negative cases had negative cultures by week 120 versus only 52% for 
participants who had an AFB score of 3, P < .05).34
The STREAM-II study, which will test bedaquiline in a nine-month injectable-free regimen, as well as a six-
month combination, finally started enrolling in March 201635—more than three years since the drug’s 
approval from the U.S. Food and Drug Administration (FDA), which was conditional upon the timely conduct 
of a phase III trial. Mongolia is the first country to start enrollment; significant MDR-TB clinical trial capacity 
development for STREAM-II should benefit the field of TB R&D overall. The Union, the study’s sponsor, 
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attributes the delay in the study’s start to the greater burden required for a registrational trial (versus the 
pragmatic design of STREAM-I, described in the next section), including the requirement for export permits 
and couriering study samples when trial host countries do not have registered laboratories. 
Despite these challenges, Janssen—bedaquiline’s sponsor—could certainly have committed more resources 
to speed bedaquiline’s entry into phase III, as required by the FDA. The gap between bedaquiline finishing 
phase IIb and entering phase III spans nearly five years; meanwhile, the paucity of data has contributed to 
the limited use of bedaquiline. Janssen’s legal department has been delaying support for another important 
and long-awaited study, ACTG study A5343, which will test delamanid and bedaquiline in combination to 
determine if together they cause unsafe levels of QT prolongation, for which each drug individually increases 
the risk. Some patients have already been treated with a combination of bedaquiline and delamanid without 
adverse events; one patient from the Democratic Republic of the Congo experienced no QT prolongation, 
but a Tibetan patient from living in India did experience asymptomatic increases in QTc from <450 to 486 
ms after eight doses of the new drugs. This observed increase was manageable, and no harm to the patient 
occurred, but it does reinforce the need for more information on the impact of the two drugs together.36,37 
Janssen’s lack of urgency on A5343, coupled with its deplorable delays on initiating pediatric research even 
after receiving public contributions to expedite it (see “Pediatric Tuberculosis Treatment Pipeline,” page 52), 
clearly point to Janssen’s plummeting contributions to TB R&D since bedaquiline’s approval—for which 
Janssen received a handsome reward of a priority review voucher as well as substantial tax credits. Janssen is 
looking into determining a breakpoint for resistance to guide drug susceptibility testing in line with the terms of 
its conditional FDA approval, though this appears to be scientifically challenging to determine.38 
Public resources are furthering bedaquiline’s research. The NExT study in South Africa, which is testing the 
drug in a six-month injectable-free regimen, has started enrolling in Cape Town, but bureaucratic delays from 
the South African Medical Research Council have meant that only one study site is open.39 Bedaquiline and 
delamanid will also be tested together and separately as part of nine-month injectable-free regimens in the 
UNITAID-funded endTB trial, which sponsors MSF and Partners In Health anticipate to begin enrollment in late 
June or early July 2016.40
 
Delamanid
Delamanid’s phase III trial, which started in a much timelier fashion than bedaquiline’s (although it was 
arguably also more urgent, given the poor design of delamanid’s phase IIb trial), is in follow-up, with 
results expected in 2018. These results, though eagerly anticipated for the information they will give about 
delamanid’s safety and efficacy, will not inform the drug’s optimal use in combinations, as the study design 
just adds it to the old WHO-recommended background regimen. The above-noted publicly funded endTB 
and A5343 trials should provide important information about delamanid’s use, as will studies MDR-end 
(sponsored by the Korean Center for Disease Control to test an injectable-free regimen of delamanid, 
linezolid, levofloxacin, and pyrazinamide against the current standard of care in people with fluoroquinolone-
susceptible MDR-TB, which is currently enrolling41), A5356 (the ACTG’s study of linezolid and delamanid 
for MDR-TB), and VTEU (sponsored by the NIH Division of Microbiology and Infectious Diseases to test a 
delamanid-containing, injectable-free MDR-TB regimen against the standard of care).42 Otsuka, delamanid’s 
sponsor, which has been the lead private-sector investor in TB R&D for years, is much more advanced than 
Janssen in terms of its pediatric (see “Pediatric Tuberculosis Treatment Pipeline,” page 52) and prevention (see 
“Tuberculosis Prevention Pipeline,” page 15) research. 
However, given Otsuka’s limited-access strategy (if one can even call it a strategy), only a few hundred 
people have received delamanid outside of clinical trials, despite the fact that up to two-thirds of people with 
MDR-TB may benefit from it, according to WHO guidance.43 Otsuka has finally made some much-needed 
and long-called-for changes, including allowing for the co-administration of bedaquiline and delamanid 
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under compassionate use, ending a formal blanket exclusion of pregnant women in the compassionate use 
program, and including delamanid in the Global Drug Facility catalogue. But this is just the tip of the iceberg, 
with approvals for delamanid still only in low-TB-burden regions of the European Union, Japan, and South 
Korea. Submissions are in progress for delamanid in China, Hong Kong, Indonesia, the Philippines, and 
Turkey.44 Otsuka has still not filed in the vast majority of high burden countries, including in trial-site countries 
of Moldova, Peru, and South Africa, and in other countries with large epidemics, such as India. Table 2 
provides a direct comparison of how each of the new drugs in phase III is faring on important research and 
access milestones. Access to bedaquiline and delamanid is particularly important as research continues to 
highlight the importance of early treatment in interrupting MDR-TB and XDR-TB, given extensive ongoing 
transmission in households, communities, and hospitals.45
 
Foul Play in the Federation: Unvalidated TB Drugs in Russia
Perchlozone and SQ109—not included in table 1, as there are no peer-reviewed clinical trial data in 
English to support their efficacy—are bulldozing their way forward into the Russian market. Perchlozone, 
developed by JSC Pharmasyntez, was approved for the treatment of MDR-TB in Russia in 2012, at a 
different dose and duration than those studied in the two small trials off which approval was based (see 
the 2013 Pipeline Report for more details). It has since been added to the List of Vital and Essential 
Medicines in Russia, and the Russian Association of Pulmonologists recommends it for empiric TB 
treatment.46 
In addition to the uncertain safety and efficacy of perchlozone, its clinical value for the treatment of 
MDR-TB might be limited because of its mode of action. A recent study demonstrated that perchlozone 
is a prodrug activated by monooxygenase EthA. This same enzyme activates the second-line drugs 
ethionamide and prothionamide47 and is frequently mutated in the dominant MDR clones in Russia, which 
therefore raises the possibility that significant rates of preexisting resistance to perchlozone might exist due 
to prior use of ethionamide or prothionamide.48 Moreover, the recommendation by JSC Pharmasyntez 
to prescribe perchlozone in combination with prothionamide is questionable.49 This underlines the 
importance of a recent call to require the elucidation of resistance mechanisms as part of the approval of 
new TB drugs, as is already the case for antivirals.50
SQ109 appears to be following an equally troubling path. Developed by Sequella, the same company 
that has been unable to move promising candidate sutezolid forward for the past three years, SQ109 
was found to have no discernable antimicrobial or clinical activity when used in combination therapy for 
drug-susceptible TB.51 Sequella licensed SQ109 to Russian company Infectex, which conducted a measly 
but putatively registrational trial of 80 patients.52 Despite the lack of a proper and robust trial, and no 
generation of peer-reviewed data or plans to do so, Sequella announced that SQ109 will be registered in 
Russia this year.53 
The use of unvalidated drugs carries great costs to the patient, society, and the economy. Perchlozone’s 
safety is unclear, its efficacy is unvalidated and may be impeded by known preexisting drug resistance, 
and its price tag of US$1,458 for three months is hefty.54 SQ109, though probably safe, has no evidence 
of efficacy, is likely to also add substantial costs to treatment, and could endanger lives if it is used instead 
of a more effective drug. The use of these drugs is not only unwarranted but dangerous. Pharmasyntez, 
Infectex, and Sequella are each acting unethically in pursuing marketing approval before clinical evidence 
supports doing so. Roszdravnadzor, the Russian regulatory authority, is failing to protect public health 
and urgently needs to change its policies to end, rather than encourage, poor science and indiscriminate 
marketing. On a troubling note, Qurient, sponsor of the above-mentioned Q203, has also arranged to 
partner with Infectex for Russia and the other CIS countries and should be extremely careful to ensure an 
ethical and scientifically rigorous approach to the development of this important new compound.
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(see Pediatric TB Treatment, 
page 52)
Enrollment started May 2016 Trial started 
June 2013; delamanid appears safe in 
children age 6 and up, with further 
results from younger age groups 
expected 2017
Trial not yet started (further 
toxicology work pending)
Phase III trial Enrollment started March 2016 Enrollment completed November 
2013; results expected 2018
Enrollment in STAND trial 
started February 2015; on 
hold since September 2015
Latent TB infection trial  
(see TB Prevention, page 15)
None Feasibility study successful; PHOENIx 
trial expected to start later in 2016
n/a
ACCESS
Number of patients 
receiving drug under 
programmatic conditions





Started Q1 2011, ended Q3 2015;
>800 patients from 47 countries enrolled
Started Q1 2014; ongoing None
Expanded access trials Started 2011 in Lithuania, Russia (application in 
China denied)
None None 
Approvals 2012: United States 
2013: Russia 
2014: EU, Peru, Philippines, South Africa, South 
Korea 
2015: Armenia, India, Turkmenistan, Uzbekistan, 
Macau (import license)
2014: EU, Japan, South Korea
2016: Hong Kong 
None 
(not pursuing accelerated 
approval; waiting for 




Azerbaijan, Bangladesh, Belarus, Brazil, Burundi, 
Cameroon, China, Colombia, Ethiopia, Ghana, 
Hong Kong, Indonesia, Kazakhstan, Kenya, Mexico, 
Moldova, New Zealand, Rwanda, Switzerland, 
Taiwan, Tanzania, Thailand, Uganda, Vietnam
Note: Kyrgyzstan rejected due to lack of phase III 
data
Turkey
(submissions in progress for China, 
Philippines, Vietnam)
None
WHO Essential Medicines List 
inclusion
Included (April 2015) Included (April 2015) n/a
Pricing Tiered pricing by country income level plus 
donation program (treatment course price: high 
US$26,000; middle US$3,000; low US$900); 
30,000 treatment courses donated to Global 
Fund–eligible countries
US$28,000–$33,000 in Europe; 
US$1,700 in Global Fund–eligible 
countries
n/a
(note: nonprofit TB 
Alliance has affordability 
commitment)
EU: European Union; WHO: World Health Organization 
n/a: not applicable as has not yet received marketing approval 
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OPTIMIZING THE USE OF APPROVED AND REPURPOSED DRUGS 
 
Rifamycins
The quest for optimizing the use of rifampin, one of the most potent TB drugs and a backbone of DS-TB 
treatment, continues with several studies planned and underway to test much higher doses than the current 
standard 10 mg/kg. A two-month study to increase the dose to 15 or 20 mg/kg showed no significant 
increase in adverse events (no grade 4 liver enzyme increases; rates of grade 3 increases in liver enzymes 
were 1% in 10 mg/kg arm vs. 2% in the 15 mg/kg arm vs. 4% in the 20 mg/kg arm, P = .15).55 Increasing 
the dose of rifampin to correct what is likely current underdosing may help reduce the pervasive resistance 
to this important drug. A recent interesting, if unvalidated, artificial model has shown rifampin is excellent at 
penetrating TB lesions, a breeding ground for bugs in people with cavitary TB disease.56 If the model and the 
hypothesis that drug penetration improves outcomes are accurate, this may also help explain the widespread 
emergence of rifampin resistance, as the lack of penetration of other drugs means rifampin is effectively given 
as monotherapy. 
Rifapentine, also in the rifamycin class, is the linchpin of shortened treatment for latent TB infection (see “TB 
Prevention Pipeline,” page 15), and is now being studied by the Tuberculosis Trials Consortium (TBTC) and 
ACTG in Study 31/A5349 for its potential—with or without moxifloxacin—to shorten DS-TB treatment to 
four months.57 Study 31 has started enrollment in Fort Worth, Hanoi, Hong Kong, Kampala, Port-au-Prince, 
and Soweto, but is behind schedule due to bureaucratic and regulatory delays. Additional funding for the 
TBTC, whose budget has either been cut or flatlined for the past several years, is critical to allow for timely 
enrollment and important additional activities such as biobanking at TBTC sites to gather as much useful data 
as possible from the study. In the meantime, additional funding for Study 31/A5349 from the NIH via the 
ACTG will support enrollment and allow for biobanking at ACTG sites.
One notable study, TRUNCATE-TB, aims to reduce treatment for most people with DS-TB to two months, using 
combinations of new and repurposed drugs, including the rifamycins. The approach taken in this trial is to 
allow larger proportions of patients to fail initial therapy than would otherwise be tolerated in conventional 
trials but treat again those who are not cured. The primary endpoint is the proportion cured at two years, 
whether or not they required additional treatment following relapse. By definition, this will result in a greater 
degree of illness in a number of participants but will benefit those who are cured quickly with shorter treatment 
durations. This is a philosophical shift from historical TB trials, which have aimed to cure as many patients 
as possible and do not tolerate relapses, which usually require longer treatment durations. The randomized 
controlled TRUNCATE-TB trial will examine four two-month regimens, compared with the standard DS-TB 
treatment. Experimental regimens involve an arm with high-dose rifampin (35 mg/kg), linezolid, isoniazid, 
pyrazinamide, and ethambutol; a second arm that is the same but substituting clofazimine for linezolid; a third 
arm that uses rifapentine, levofloxacin, linezolid, and pyrazinamide; and a fourth arm that has bedaquiline, 
linezolid, isoniazid, pyrazinamide, and ethambutol. TRUNCATE-TB has complete protocol and ethics 
committee approvals in the United Kingdom and Singapore and should begin enrollment by the end of 2016. 




Fluoroquinolones are arguably the most important element in MDR-TB treatment; resistance to 
fluoroquinolones greatly increases the likelihood of a poor outcome.59 As such, several studies for MDR-
TB continue to use fluoroquinolones. A recent randomized controlled trial in Korea compared treatment 
outcomes from levofloxacin or moxifloxacin and found they had similar treatment success rates (84.4% vs. 
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79.7%, P = .53 [a nonsignificant difference]), though rates of musculoskeletal adverse events were higher 
in those receiving levofloxacin (37.7% vs. 14.9%, P = .001).60 Because moxifloxacin causes higher QT 
prolongation than levofloxacin, knowing levofloxacin has comparable efficacy is very useful in designing 
regimens with other QT-prolonging drugs, such as bedaquiline and delamanid. The Opti-Q study, sponsored 
by Boston University and the U.S. National Institute of Allergy and Infectious Diseases, is exploring the best 
dose for levofloxacin and should have results in 2018.61,62 
Moxifloxacin is being used in the STREAM-I trial, a nine-month regimen for MDR-TB based on the modified 
Bangladesh regimen of multiple existing drugs (described in previous Pipeline Reports), including an injectable 
and clofazimine. Follow-up is ongoing; in the meantime, this regimen has received WHO endorsement for 
use in previously untreated patients with rifampicin-resistant TB or MDR-TB.63 The recommendation is based 
on observational cohort data, with very low certainty in the evidence, calling into question the rationale for 
and the objectivity of recommending this regimen. Randomized controlled clinical trial data are essential 
for understanding how well this regimen truly works in the indicated population, and scale-up of drug 
susceptibility testing (see “TB diagnostics pipeline,” page 1) must accompany shortened regimen rollout. 
However, given that the brutal 18–24-month standard of care for MDR-TB has also not been validated in 
randomized controlled clinical trials and is very difficult for patients, many may be eager for access to a 
shortened regimen. 
Also controversially, gatifloxacin, used in the original Bangladesh regimen and then abandoned due to safety 
concerns, recently received endorsement in the new WHO MDR-TB treatment guidelines. 64 Like levofloxacin, 
gatifloxacin has less risk of QT prolongation than moxifloxacin, and observational studies and the OFLOTUB 
trial did not indicate safety issues (though in the trial the drug was only given for four months).65 While more 
drugs in the arsenal to treat TB are helpful, re-adding gatifloxacin is confusing for countries and further 
fragments the challenging market for MDR-TB drugs, especially because there is no current quality-assured 
source of gatifloxacin due to its withdrawal from the market over safety concerns and because supporting 
evidence is of very low quality. 
Because of the fluoroquinolones’ good activity against TB, they continue to be examined for shortening 
treatment for DS-TB, for example in the above-mentioned TBTC Study 31 and as part of TRUNCATE-TB. 
Of note, the FDA has recently recommended against the routine use of fluoroquinolones for more minor 
infections such as acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections when other 
treatment options exist, noting that because of serious side effects, the harms outweigh the benefits, so for 
these conditions, fluoroquinolones should be reserved for those without alternative treatment options.66 This 
does not apply to MDR-TB and DS-TB, which are certainly more serious conditions, but does again point to 
the need for safer, better treatment options more generally for TB. 
 
Clofazimine
Clofazimine, a riminophenazine long used for the treatment of leprosy and off-label for MDR-TB, is 
finally moving toward formal evaluation for TB in randomized controlled trials. Novartis has planned 
study CLAM320B2202, a phase IIb/III randomized, open-label trial to evaluate the efficacy and safety of 
clofazimine (at 200 mg once daily for six months followed by 100 mg once daily for the remaining 12 to 18 
months of treatment) plus background regimen compared with background regimen alone in people with 
MDR-TB. Enrollment was anticipated to start in March 2016 but is now projected to start in April 2017.67 
The ACTG is planning a phase IIc study of clofazimine, added to standard therapy with a treatment duration 
of four months, for DS-TB. Clofazimine also plays an important role in the above-mentioned ongoing and 
planned PRACTECAL, STREAM-I, STREAM-II, and endTB studies.
45
Tuberculosis Treatment
The new WHO MDR-TB treatment guidelines recognize clofazimine’s and linezolid’s importance, elevating 
them as “core second-line agents” on par with cycloserine/terizidone and ethionamide/prothionamide and 
preferable to para-aminosalicylic acid for constructing a regimen.68
 
Linezolid
Linezolid, of increasing importance for MDR- and XDR-TB, has manageable but nonetheless challenging side 
effects, including painful nerve damage. The TB Alliance examined the early bactericidal activity (EBA) of 
linezolid over two weeks as part of its efforts to determine an ideal dose and dosing schedule for linezolid to 
support the above-mentioned NiX-TB trial. The study found that all daily doses, from 300 mg to 1,200 mg, 
given as either once-daily or twice-daily doses, demonstrated EBA, and there was a statistically significant 
dose response from 300 mg to 1,200 mg daily, indicating that higher doses provided greater activity, with 
no difference between once- and twice-daily dosing for the same total daily dose. As a result, the TB Alliance 
has changed the NiX study dosing of linezolid from 600 mg twice to 1,200 mg once a day.69 Mouse model 
data suggest that linezolid may only be needed for one to two months, which might also be worth exploring in 
clinical trials. 
As noted previously, linezolid availability is critical to the successful rollout of bedaquiline. One-year 
posttreatment outcome data from a small clinical trial of linezolid in South Korea whose four-month sputum-
culture conversion data were previously reported further indicate that linezolid is an important drug for treating 
XDR-TB. Of 38 patients receiving linezolid, 27 had negative results on sputum culture one year after treatment 
end, 3 were lost to follow-up, and 8 withdrew from the study (including 4 who failed on linezolid treatment, 
as previously reported). Of the 27 participants completing the study, 4 had a dose reduction from 600 to 300 
mg. Among 13 participants assigned to continue receiving 600 mg, 9 had to reduce the dose to 300 mg due 
to adverse effects. All serious adverse events resolved after the discontinuation of linezolid. Though the study 
design was questionable, as linezolid was effectively given as monotherapy, only 4 out of 38 participants, 
or 11% of those receiving linezolid, developed resistance to linezolid. In total, 27 of 38 patients (71%) with 
chronic XDR-TB were cured at one year after termination of treatment.70
To inform the use of linezolid for people with HIV on ART, a retrospective study of linezolid use for the 
treatment of pre-XDR-TB and XDR-TB in people with HIV in Khayelitsha, South Africa, and Mumbai, India, 
showed that the rate of culture conversion in patients treated with linezolid is better than previously reported 
among XDR-TB cohorts and that people with HIV on ART were able to tolerate prolonged linezolid exposure, 
adding to the body of evidence supporting linezolid’s use in challenging cases.71 Recent efforts to increase 
generic competition and bring down prices for linezolid in South Africa have been successful thanks to strong 
advocacy.72 The Global Drug Facility has announced a 70% decrease in the price of linezolid.73
 
Carbapenems
Carbapenems such as meropenem and imipenem are beta-lactams—antibiotics with a good safety profile 
and low potential for interaction with antiretrovirals. Historically, they have received little attention for TB 
because of the high intrinsic resistance of mycobacteria to these drugs, although this can be overcome with 
the addition of amoxicillin/clavulanate.74 Carbapenems have been used more frequently due to the need for 
companion drugs for bedaquiline. A recent proof-of-concept randomized controlled study gave two kinds of 
carbapenems—orally available faropenem (at 600 mg three times a day) or intravenous meropenem (at 2 
g three times a day)—or the standard of care for 14 days to people (15 in each arm) with untreated, DS-
TB. This study found that faropenem had no detectable EBA: estimated fall in log10 colony-forming units was 
0.00 (95% confidence interval [CI]: −0.002 to 0.002, P value vs. control < .001), likely due to the very low 
exposures to the drug measured in in blood during the trial. In contrast, meropenem had good EBA, with a 
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fall in log10 colony-forming units of 0.11 (95% CI: 0.009 to 0.13) versus the control’s 0.17 (95% CI: 0.15 to 
0.19), though the control was still significantly better (P < .001).75 Meropenem use was not associated with 
any grade 3 or 4 events (compared with four in the control arm and three in the faropenem arm). Diarrhea 
was observed frequently in both the meropemen and faropenem arms, likely from the amoxicillin/clavulanate. 
The study’s findings indicate the need for further optimization of the use of this class for TB, including 
determining whether amoxicillin/clavulanate is necessary, reducing dosing to once or twice daily, prioritizing 
the development of orally bioavailable carbapenems, and testing faropenem medoxomil (an unapproved 
formulation that may have higher exposures and EBA against TB than faropenem alone) for use against TB.
Ertapenem, another carbapenem, may merit further study. A recent retrospective study in the Netherlands of 
12 patients who received ertapenem as part of their treatment between 2010 and 2013 and in whom drug 
exposure was evaluated showed that ertapenem was well tolerated and had a favorable pharmacokinetics/
pharmacodynamics profile in people with MDR-TB. Though not orally available, ertapenem requires only 
once-daily dosing, in contrast to meropenem’s thrice-daily dosing.76 
 
RECOMMENDATIONS
1. Government agencies, pharmaceutical companies, and foundations must dramatically scale 
up funding for TB R&D. In line with the third pillar of the WHO’s End TB strategy, which calls for R&D, 
countries must commit more resources to TB drug development.77 The U.S. government, which is the 
leading funder of TB R&D, should increase funding levels to $300 million by 2018 to keep its critical 
investments at pace with inflation. TAG suggests that this should entail an additional $17 million from the 
NIH, $15 million from USAID, $16 million from the U.S. Centers for Disease Control and Prevention, and 
$5 million from the FDA for TB R&D.78 European Union countries, particularly Germany, should double 
their TB R&D funding, and Brazil, China, India, Russia, and South Africa should each triple their funding 
for TB R&D.79 Activists in other countries should call for commensurate increases in their own settings. 
 
Companies such as Otsuka and Sanofi should maintain strong levels of investment, and Janssen needs to 
recommit to further developing bedaquiline, as significant work remains despite bedaquiline’s conditional 
approval, and to moving the most promising of its pipeline of bedaquiline analogues further toward 
clinical study. Other pharmaceutical companies and philanthropic organizations should also begin to 
invest in TB R&D.
2. Donor and high-TB-burden governments should create and invest in mechanisms that build 
access to TB drug development, and drug developers should participate in them. The inability to 
access data hampers collaborative TB drug development, which is essential because TB must be treated 
with a combination of drugs to prevent the development of resistance. The inability to access drugs 
hampers TB treatment and cure and threatens to render the limited R&D that is occurring less useful. 
Fortunately, members of the TB community have proposed feasible and appealing solutions that should be 
actively pursued. These include remedying loopholes in the FDA’s priority review voucher system to ensure 
innovation and drug availability and fair pricing80 and should also entail product developers licensing 
their compounds to and sharing data with the MPP, which recently received a mandate to work on TB 
drug development and could possibly play a key role in brokering combination drug development.81 
MSF’s proposed 3P (“Push, Pull, Pool”) project may also provide an interesting, innovative, and potentially 
transformative approach to spur the development of regimens and ensure their availability post-approval, 




3. Drug and trial sponsors must expedite the development of preclinical and clinical candidates. 
Delays in TB research and development are widespread and atrocious. The TB drug development 
pipeline remains frighteningly sparse, pointing to the urgent need to advance preclinical work to allow 
viable candidates into clinical studies. Clinical development for the few products in the pipeline has been 
unacceptably slow, with drugs taking over five years to advance from one stage to the next. In particular, 
Janssen’s and Sequella’s failures to rapidly move bedaquiline and sutezolid, respectively, through 
important studies are deplorable.
4. Ministries of health, regulatory authorities, and ministries of finance should prioritize the timely 
introduction of evidence-based TB treatment, and donors and providers of technical assistance 
should ensure they are supporting rather than hindering scale-up. Drug development will not affect 
the TB epidemic and improve the lives of people affected by TB unless new interventions are available 
to communities and people who need them. Unfortunately, country-level demand for important new 
products such as delamanid and bedaquiline has been weak, and implementation slow. USAID, which has 
partnered with Janssen to make bedaquiline available via a donation program, literally cannot give the 
drug away for free to enough people. Poor advice from technical assistance providers has worsened the 
situation and excused complacency. All parties, national and global, must be much more ambitious and 
supportive of new ways to find and treat TB.
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The Pediatric Tuberculosis Treatment Pipeline:  





The roster of enrolling and planned pediatric tuberculosis (TB) treatment studies is growing. Emerging results 
from pharmacokinetics (PK) and safety studies continue to inform optimal dosing strategies in children and to 
highlight areas in need of further investigation. New pediatric formulations continue to advance to market, 
and consensus has begun to form around the need for efficacy studies of simplified multidrug-resistant TB 
(MDR-TB) treatment regimens in children.
 
PEDIATRIC PIPELINE OVERVIEW
Studies that are under way or starting soon will evaluate preventive therapy for children exposed to MDR-TB 
and treatment shortening for less severe forms of drug-sensitive TB (DS-TB) in children, as well as fill gaps in PK 
and safety data that are necessary to optimize treatment, including in HIV-positive children and children with 
MDR-TB. Table 1 provides an overview of ongoing and planned pediatric TB prevention and treatment studies.
 
Table 1. Ongoing and Planned TB Prevention and Treatment Studies in Children
Study/Regimen Status Population(s) Sponsor(s)
PREVENTION
P4v9





HIV-positive and HIV-negative infants, 




PK and safety of rifapentine/isoniazid FDC for 
prevention of TB
Planned; opening 2017 HIV-positive and HIV-negative infants, 




6 months of levofloxacin vs. placebo for prevention 
of MDR-TB
(substudy planned using delamanid for child 
contacts of FQ-R TB patients)
Planned; opening 2016 HIV-positive or HIV-negative infant and 
child household contacts 0–5 years 
old; children ≤5 years old will get new 
pediatric formulation
BMRC, Wellcome Trust, 
DFID, SA MRC
ACTG A5300/IMPAACT P2003 (PHOENIx)
6 months of delamanid vs. isoniazid for prevention 
of MDR-TB
Planned; opening late 
2016/early 2017
High-risk (HIV+, TST+, or ≤5 years) infant, 
child,  adolescent, and adult household 
contacts of index patient with MDR-TB
NIAID
V-QUIN
6 months of levofloxacin vs. placebo for prevention 
of MDR-TB
Planned; opening 2016 HIV-positive or HIV-negative adult 
household contacts; phased inclusion of 
infant, child, and adolescent contacts
NHMRC




Study/Regimen Status Population(s) Sponsor(s)
TREATMENT – NEW DRUGS
232 
PK and safety of delamanid; OBR for treatment of 
MDR-TB
NCT01856634*
Enrolling; final results 
expected 2018
HIV-negative infants, children, and 
adolescents 0–17 years old with MDR-TB; 




6 months of delamanid; OBR for treatment of 
MDR-TB
NCT01859923*
Enrolling; final results 
expected 2020
HIV-negative infants, children, and 
adolescents 0–17 years old with MDR-TB; 




PK and safety of delamanid; all oral OBR for 
treatment of MDR-TB
Planned HIV-positive or HIV-negative infants, 




PK and safety of bedaquiline; OBR for treatment 
of MDR-TB
NCT02354014*
Enrolling HIV-negative infants, children, and 
adolescents 0–18 years old with MDR-TB; 





PK and safety of bedaquiline; OBR for treatment 
of MDR-TB
Planned; opening 2016 HIV-positive or HIV-negative infants, 
children, and adolescents 0–18 years old 
with MDR-TB
NIAID
TREATMENT – EXISTING DRUGS
Treat Infant TB
PK and safety of FLDs using 2010 WHO dosing 
guidelines for treatment of TB
Enrollment complete; 
results presented 2015
HIV-positive or HIV-negative infants <12 
months old with TB
UNITAID/TB Alliance  
(STEP-TB Project)
PK-PTBHIV01
PK of FLDs using 2010 WHO dosing guidelines for 
treatment of TB 
NCT01687504*
Enrollment complete; 
interim results presented 
2015; final results 
expected 2016
HIV-positive or HIV-negative children 3 
months to 14 years old with TB
NICHD
OptiRif Kids
PK, safety, and dose optimization of rifampin for 
treatment of TB
Planned; opening 2016 HIV-positive or HIV-negative infants and 
children ≤5 years old with TB
TB Alliance
SHINE
4 vs. 6 months using 2010 WHO dosing guideline–
adjusted FLD FDCs for treatment of minimal TB
Planned; opening 2016 HIV-positive or HIV-negative infants, 
children, and adolescents 0–16 years old 
with minimal TB
BMRC, DFID, Wellcome 
Trust, UCL
TBM-KIDS
Safety and efficacy of high-dose rifampin ± 
levofloxacin for treatment of TBM




PK and safety of SLDs for treatment of MDR-TB
Enrollment complete; 
interim results presented; 
final results expected 2016
HIV-positive or HIV-negative infants, 




PK, safety, and dose optimization of SLDs for treat-
ment of MDR-TB
Enrolling; results expected 
2020
HIV-positive or HIV-negative infants, 




Study/Regimen Status Population(s) Sponsor(s)
COTREATMENT WITH ARVS
DATiC
PK of FLDs using 2010 WHO dosing guidelines for 
treatment of TB and interactions with lopinavir/
ritonavir and nevirapine
NCT01637558*
Enrolling; results expected 
2017
HIV-positive or HIV-negative infants, 




PK of rifampin and isoniazid with nevirapine or 
lopinavir/ritonavir
NCT02383849*
Enrolling; results expected 
2018
HIV-positive or HIV-negative low-birth-
weight/ premature infants
NIAID, NICHD
PK and safety of nevirapine with rifampin-
containing TB treatment
NCT01699633*
Enrolling; results expected 
2017









HIV-positive children 3 months to  
<3 years old with TB 
NIAID, NICHD 
PK and safety of efavirenz with rifampin-
containing TB treatment
NCT01704144*
Enrolling; results expected 
2017
HIV-positive children and adolescents 
3–14 years old with TB
NICHD
HIVPED001
PK and safety of superboosted lopinavir/ritonavir 
(1:1) with rifampin-containing TB treatment
NCT02348177*
Enrolling; interim results 
presented 2015; final 
results expected 2016
HIV-positive infants and children with TB 
weighing 3–15 kg; DNDi developing stand-
alone ritonavir booster formulation
DNDi, AFD, UBS Optimus 
Foundation, MSF
IMPAACT P1101
PK and safety of raltegravir with rifampin-
containing TB treatment
NCT01751568*
Enrolling; results expected 
2018
ARV-naive, HIV-positive children and 
adolescents 2–12 years old with TB
NIAID
*U.S. National Institutes of Health (NIH) clinical trial identifiers; for more information, go to ClinicalTrials.gov.
AFD: French Development Agency
ART: antiretroviral therapy
ARV: antiretroviral
BMRC: British Medical Research Council
CIHR: Canadian Institutes of Health Research
DFID: Department for International Development (United Kingdom)




IMPAACT: International Maternal, Pediatric, Adolescent AIDS Clinical Trials
   Group, NIH
LTBI: latent tuberculosis infection
MDR-TB: Multidrug-resistant tuberculosis
MSF: Médecins Sans Frontières
NHMRC: National Health and Medical Research Council (Australia)
NIAID: National Institute of Allergy and Infectious Diseases, NIH
NICHD: National Institute of Child Health and Human Development, NIH
OBR: optimized background regimen
PK: pharmacokinetics




TBTC: Tuberculosis Trials Consortium, U.S. Centers for Disease Control and
   Prevention
TST: tuberculin skin test
UBS: Union Bank of Switzerland
UCL: University College London
WHO: World Health Organization
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TB drugs and regimens with proven efficacy in adults have long been assumed to work at least equally as well 
in children. Typically, PK and safety studies are conducted in children only to inform appropriate dosing and to 
confirm safety and tolerability; efficacy studies are therefore not usually considered to be necessary. 
However, given the paucibacillary nature of TB disease in children (characterized by fewer TB bacteria in the 
body), it might be possible to achieve a cure using shorter, milder regimens than those that are necessary in 
adults. This logic underpins SHINE, a study to evaluate whether it is possible to shorten standard first-line 
treatment from six to four months for less severe forms of pulmonary and extrapulmonary TB in children. There 
is an urgent need to conduct a similar evaluation to shorten treatment for children with less severe MDR-TB; 
conversations about what this regimen and study might look like are ongoing. Regimens for children with 




Data from ongoing pediatric PK and safety studies continue to contribute findings that are important for 
optimizing TB treatment for children. Here we present recent research updates and discuss remaining research 
needs for first-line, second-line, and new TB drugs in children. For a comprehensive discussion of available 
evidence and recommended doses for TB drugs in children, see the review Antituberculosis Drugs in Children, 
from Schaaf, Garcia-Prats, and Donald.1
 
First-Line Drugs
A study of first-line treatment in infants in Cape Town, South Africa (Treat Infant TB; N = 39), using doses 
recommended by the WHO, found that 35 mg/kg (recommended range: 30–40 mg/kg) of pyrazinamide 
and 15 mg/kg (recommended range: 10–20 mg/kg) of isoniazid achieved drug exposures in infants that 
are comparable to those in adults. Exposures following 15 mg/kg (recommended range: 10–20 mg/kg) of 
rifampin and 20 mg/kg (recommended range: 15–25 mg/kg) of ethambutol were lower than those achieved 
in adults. HIV-positive infants taking ARVs (abacavir, lamivudine, and lopinavir/ritonavir) achieved lower 
pyrazinamide and ethambutol exposures than did HIV-negative infants.2,3 
Another study of first-line treatment using WHO-recommended doses in Durban, South Africa, in children 10 
years old or younger found exposures for rifampin, isoniazid, and pyrazinamide below those associated with 
optimal microbiological and clinical outcomes in adults.4
A study of first-line treatment in infants and children in Ghana (PK-PTBHIV01; N = 62; 47% of children less 
than five years old), again using WHO-recommended doses, found that 59% of children had low exposures 
to rifampin and 52% of children had low exposures to ethambutol.5,6 
A recent study in Vietnamese children 15 years of age or younger found rifampin concentrations in 
cerebrospinal fluid below the minimum inhibitory concentration (minimum drug concentration required 
to inhibit mycobacterial growth) for almost all children treated for TB meningitis using pre-2010 WHO-
recommended doses.7 These findings support planned work to investigate the use of higher doses of rifampin 
for TB meningitis (TBM-KIDS). Further research is urgently needed to establish optimal drug combinations and 
doses for the treatment of pediatric TB meningitis.
Despite good treatment outcomes, investigators continue to find lower drug exposures measured by Cmax 
(peak drug exposure) and area under the curve (AUC, or total drug exposure) in children compared with 
adults. It is important to note a recently demonstrated association between low TB drug levels and poor 
outcomes in children. A study in India comparing PK for rifampin, isoniazid, and pyrazinamide in HIV-
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positive and HIV-negative children receiving thrice-weekly TB treatment found that the Cmax of rifampin and 
pyrazinamide significantly affected TB treatment outcomes.8 These findings support the higher and daily doses 
recommended by the WHO and underscore the need to identify PK targets that correlate with good outcomes 
in children and the drug doses that are necessary to achieve them. Low rifampin exposures in children are 
of special concern for the treatment of more severe forms of TB and in light of plans to evaluate shorter 
regimens.
Children experience a broad spectrum of TB disease, ranging from severe TB (e.g., TB meningitis) in young 
children to limited pulmonary disease to cavitary disease in adolescents. Optimal drug doses and treatment 
durations likely differ by disease type (extent and location). It is critical to determine which PK values correlate 
most precisely with efficacy for TB drugs in children. This information is necessary to optimize pediatric dosing, 
which is especially important in the context of simplified and shortened regimens for DS-TB and drug-resistant 
TB (DR-TB) and in treating more severe forms of TB.
Findings from these studies point to the need for investigations to determine PK targets for children, especially 
considering differences in bacterial burden and severity and location of disease; to elucidate optimal age- 
and weight-based dosing schedules in infants and young children; and to optimize dosing for first-line TB 
drugs in children younger than five years. In addition, as investigators continue to study higher doses of 
rifampin in adults without finding toxicity (see “Tuberculosis Treatment Pipeline,” page 35), higher doses 
should be considered in children and evaluated in future PK and safety studies. Some work is already under 
way or being planned, including a study to evaluate the PK and safety of higher doses of rifampin in children 
0–12 years old with severe and nonsevere forms of TB (OptiRif Kids). This dose-finding and safety study will 
explore the drug doses in children necessary to achieve the PK exposures shown to be safe, well tolerated, 
and associated with improved TB killing activity in recent adult studies.9
 
Cotreatment with ARVs
Rifampin (a rifamycin) induces drug metabolism by increasing the amount of drug-metabolizing enzymes in 
the liver.10 As a result, rifampin interacts with many other drugs, including anti-HIV compounds such as the 
non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine and the protease inhibitors lopinavir 
and ritonavir. Studies are necessary to characterize these drug-drug interactions and to determine whether 
dose adjustments are necessary or contraindications exist.
Efavirenz, which has minimal interactions with rifampin, is an important treatment option for people coinfected 
with TB and HIV, but PK variability and formulation issues have precluded its use in children younger than 
three years. A PK study using higher doses of efavirenz (65 mg/kg) in TB/HIV-coinfected children 3–36 months 
old (P1070) found therapeutic efavirenz concentrations in children with fast metabolism of drugs processed 
by the cytochrome P450 2B6 enzyme (encoded by the CYP2B6 gene). The investigators concluded that a 
lower dose is likely to be necessary for TB/HIV-coinfected children with slow CYP2B6 metabolism.11 This study 
demonstrates that optimal exposure to efavirenz can be achieved in coinfected children younger than three 
years but requires pretreatment genotyping with pharmacogenomic assays that are expensive and not widely 
available. 
A study of rifabutin, an alternative to rifampin that is more forgiving in adults on protease inhibitor–based 
antitretroviral therapy (ART), in HIV-positive children younger than five years receiving lopinavir/ritonavir closed 
early due to safety concerns. In the six children who completed the study prior to closure, rifabutin dosed at 5 
mg/kg three times a week resulted in lower AUC and Cmax values for rifabutin and its metabolite compared 
with those in adults receiving the recommended dose of 150 mg rifabutin daily. In addition, high rates of 
severe transient neutropenia (characterized by low concentrations of white blood cells that are important for 
fighting infections) were observed.12 It is unclear whether a safe and effective rifabutin dose exists for TB/HIV-
coinfected children on protease inhibitor–based ART.
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Interim results from a study evaluating superboosted lopinavir/ritonavir administered in a ratio of 1:1 
(standard lopinavir/ritonavir is administered in a ratio of 4:1) with rifampin-containing TB treatment to infants 
and young children (HIVPED001) found that exposures to lopinavir/ritonavir (1:1) with rifampin were not 
inferior to exposures to lopinavir/ritonavir (4:1) without rifampin. Virological efficacy and safety were also 
comparable. However, problems with existing lopinavir/ritonavir formulations and tolerability remain.13 
Given the challenges presented by interactions between protease inhibitors and rifamycins, integrase inhibitors 
may provide a good alternative for young TB/HIV-coinfected children. PK and safety studies for integrase 
inhibitors, notably dolutegravir and raltegravir, are under way for children and infants14 (see “Pediatric 
Antiretroviral Pipline,” in 2016 Pipeline Report), and the International Maternal, Pediatric, Adolescent AIDS 
Clinical Trials (IMPAACT) Network is planning to evaluate the PK and safety of raltegravir administered with 
rifampin-containing anti-TB treatment to children 2–12 years old (P1101). 
 
Second-Line Drugs
In addition to the preliminary PK and safety data covered by previous reports,15,16 further analyses from  
MDR-PK 1, which completed enrollment in 2015, are presented here for ofloxacin, levofloxacin, and 
amikacin. More data will be disseminated throughout 2016, including those on moxifloxacin and linezolid.
Children given ofloxacin at 15–20 mg/kg as whole or crushed tablets for treatment (N = 55) or prevention 
(N = 30) of MDR-TB had peak exposures slightly lower than, but comparable to, those achieved in adults. 
Total exposures were far below the targets achieved in adults—likely because of more rapid drug clearance 
in children. Higher Cmax values were observed in children receiving crushed versus whole tablets (statistically 
insignificant), but AUCs remained unaffected. Peak exposures were higher among younger children, but 
increased with total exposure and weight. No difference was observed in children coinfected with HIV. 
Ofloxacin appeared to be safe, with no grade 3 or 4 adverse events in 46 children followed for a median of 
150 days.17,18 Of the fluoroquinolones, moxifloxacin and levofloxacin are generally considered to be superior 
to ofloxacin, but given cost, availability, and formulation constraints, ofloxacin is still used in children in some 
settings.
Previously published data on levofloxacin dosed at 15 mg/kg in children show low drug exposures compared 
with those achieved in adults.19 Using additional PK data from children given levofloxacin at 15 mg/kg 
and 20 mg/kg (N = 109) and pharmacometric modeling, researchers have determined that the 20 mg/kg 
dose more closely approximates adult exposures.20 However, there is room to further optimize levofloxacin 
exposures in children, and studies are under way (MDR-PK 2).
Age influenced the AUC, but not the Cmax, when amikacin was given to children (N = 96) at 15–20 mg/kg 
(recommended range: 15–30 mg/kg). There was no effect on exposure by HIV status. Based on these and 
earlier data, to achieve exposures similar to those in adults, the investigators suggest that amikacin be given 
to children at a dose of 18–20 mg/kg.21 Hearing loss (associated with cumulative amikacin exposure) has not 
yet been analyzed in this cohort, but has been previously reported in up to 24% of children in this setting.22
Further analyses of the data collected in MDR-PK 1 are planned for high-dose isoniazid, ethionamide, para-
aminosalicylic acid, and linezolid. MDR-PK 2, which opened in October 2015, will build on the evidence 
collected in MDR-PK 1 to further optimize the use of key second-line drugs in children, including moxifloxacin, 
levofloxacin, and linezolid. MDR-PK 2 incorporates a crossover design to allow for the collection of PK data 
on moxifloxacin and levofloxacin in children across all ages; children younger than eight years are typically 
only given levofloxacin due to the limitations of the existing formulation of moxifloxacin, a large unscored 
tablet that is bitter when crushed. MDR-PK 2 will look more closely at bioavailability when moxifloxacin 




The PK and safety data presented here and still being collected are critical to informing dosing for first- and 
second-line TB drugs in children. However, several ongoing or planned treatment-shortening studies in adults 
use higher doses of key first- and second-line drugs (see “Tuberculosis Treatment Pipeline,” page 35). It is 
imperative that these treatment-shortening studies collect data on ideal PK values in adults, as this information 
is necessary to inform appropriate, evidence-based dosing in children.
In May 2016, the WHO issued an update to its guidelines for treating MDR-TB. Based on data in adults,  
the guidelines recommend that children with confirmed rifampin-resistant or MDR-TB be given the same  
consideration for treatment with a shorter MDR-TB treatment regimen as adults.24 However, this 
recommendation is likely to have limited reach given the challenges of obtaining viable samples for 
microbiologically confirmed diagnosis of TB in children (see “Tuberculosis Diagnostics Pipeline,” page 1). 
Another pediatric recommendation that was included in the WHO’s 2016 update to the MDR-TB treatment 
guidelines and is likely to have much broader implications is for the exclusion of injectable agents from 
regimens for children with nonsevere disease.25 This recommendation was based on consideration of the 
potential harms associated with the injectable agents, namely hearing loss and pain with administration, and 
meta-analysis of individual patient data, which points to insignificant differences in rates of treatment success 
among children with clinically diagnosed and nonsevere disease treated with or without an injectable agent.26
 
New Drugs
After one year of follow-up for the first age cohort (12–17 year olds) enrolled in C232/C233 (a pediatric PK 
and safety study of delamanid in HIV-negative children), Otsuka found six months of twice-daily delamanid 
administered at 100 mg to be safe and well tolerated. Delamanid exposures in the adolescent cohort were 
slightly higher than but comparable to, those achieved in adults, suggesting that the standard adult dose for 
delamanid is adequate for adolescents.27 
Follow-up for the second age cohort (6–11 year olds), who received 50 mg of delamanid twice daily, 
is ongoing, and enrollment for the third cohort (3–5 year olds), using the pediatric formulation, is half 
completed. A modification to Otsuka’s Pediatric Investigation Plan, agreed to by the European Medicines 
Agency (EMA), will allow for the final cohort (0–2 year olds) to enroll in parallel. This sets an important 
precedent for the parallel enrollment of pediatric cohorts, which is expected to help expedite access to new 
drugs for younger children.28 Despite the encouraging pace at which Otsuka’s pediatric investigations are 
progressing and the recent inclusion of delamanid in the Global Drug Facility (GDF) catalogue, delamanid 
has been registered only in the European Union, Japan, and South Korea. Routine access is likely to be an 
issue for years to come (see “Tuberculosis Treatment Pipeline,” page 35). 
The WHO is planning an update to its guidance on the programmatic use of delamanid before the end of 
2016 and will consider the available PK and safety data in children as young as six years.29 Rapid release of 
its guidelines will be necessary to ensure that policy is not a barrier to access for children. In the meantime, 
the Sentinel Project on Pediatric Drug-Resistant Tuberculosis has released rapid clinical advice on the use 
of delamanid and bedaquiline in children.30 Country programs shouldn’t wait, but many programs will not 
procure or use delamanid for children without formal recommendation from the WHO in the form of updated 
treatment guidelines. This underscores the importance of WHO processes that allow for more rapid review 
and incorporation of emerging data into guidelines for children.
In contrast, bedaquiline is much more widely available to adults under programmatic conditions, but children 
have virtually no access to it due to lack of data. Janssen’s PK and safety study of bedaquiline in HIV-negative 
children (C211), which has been in development for over five years, finally opened to enrollment in May 
2016.31 Janssen’s lack of experience setting up pediatric MDR-TB studies, the paucity of adequately prepared 
trial sites independent of those participating in established pediatric research networks like the IMPAACT 
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Network, and apparent pushback from regulators were among the reported causes of the study’s severely 
delayed start.32 In an effort to expedite the study, Janssen is now exploring additional trial sites in Ethiopia, 
India, and the Philippines.33
To further hasten the investigation of bedaquiline in children, Janssen should make its pediatric formulation 
available free of charge for complementary studies, including P1108, a pediatric PK and safety study of 
bedaquiline that will include HIV-positive and HIV-negative children with MDR-TB.34  
Box 1. Inclusion of Pregnant Women in TB Research 
An estimated 3.2 million women develop TB each year; conservative models estimate that 
216,500 of them are also pregnant, but these data are not collected.35 TB is one of the 
leading non-obstetric causes of death among pregnant women, accounting for 28% of 
maternal deaths globally.36 Currently, treatment of TB during pregnancy is done with minimal 
specific guidance and with a lack of information on the effects of physiological and metabolic 
changes that occur during pregnancy on drug metabolism and achieved drug exposures. 
Pregnant women are systematically excluded from TB research, and, as a result, clinicians are 
forced to use old and sometimes new TB drug regimens in pregnant women with TB without 
any guidance on safety, efficacy, or dose adjustments—or, even worse, to deny them treatment 
for lack of options. 
An expert panel convened by the NIH recently published a consensus statement advocating 
for the earlier inclusion of pregnant and postpartum women in TB drug trials and outlining 
priority research needs.37 The few ongoing or planned TB prevention and treatment studies in 
pregnant women are presented in table 2. 
In line with a 1994 report by the Institute of Medicine, which recommends that pregnant 
women be “presumed eligible for participation in clinical studies,”38 TB researchers should 
assume inclusion, and then, on an individual trial basis, think carefully about safety and 
whether the balance of risks and benefits warrants the exclusion of pregnant women from 
TB drug trials. In fact, expert consensus statements, regulatory frameworks, and guidance 
documents already exist to facilitate the appropriate and earlier inclusion of pregnant women 
in research.
Additionally, a registry, similar to the Antiretroviral Pregnancy Registry, should be established 
for pregnant women with TB to prospectively monitor birth defects in infants exposed to TB 
drugs in utero, provide early warning of major teratogenicity (ability to induce congenital 
malformations), and help estimate risk of birth defects. In the absence of clinical trials data, a 





Table 2. Ongoing and Planned TB Prevention and Treatment Studies in Pregnant Women
Trial Phase TB type Study purpose
PREVENTION
IMPAACT P1078 (TB APPRISE)
NCT01494038*
IV DS-TBI To evaluate antepartum vs. postpartum isoniazid preventive therapy in HIV-positive women
IMPAACT P2001
NCT02651259*
I/II DS-TBI To evaluate the pharmacokinetics and safety of once-weekly rifapentine and isoniazid in pregnant 








IV DS-TB To evaluate the pharmacokinetic interactions among depo-medroxyprogesterone acetate, rifampin, 
and efavirenz in women co-infected with HIV and TB
TB pregnancy registry IV DS-/DR-TB To evaluate maternal and infant treatment and safety outcomes from clinical research databases 
(planned)
*NIH clinical trial identifiers; for more information, go to ClinicalTrials.gov.
DR-TB: drug-resistant tuberculosis DS-TB: drug-sensitive tuberculosis DS-TBI: drug-sensitive tuberculosis infection
 
PEDIATRIC FORMULATIONS IN THE PIPELINE
In dose or form, preexisting pediatric formulations and preparations of TB drugs have been inadequate.40 
However, new pediatric fixed-dose combinations (FDCs) provide a rare occasion for celebration. Anticipated 
additional advances in pediatric formulation development should be approached with tempered optimism, as 
much remains to be done. Table 3, presented at the end of this section, provides an overview of the pediatric 
formulations new to market and in development.
 
First-Line Drugs
Five years after the WHO increased the recommended doses for first-line TB drugs in children, and following 
significant investments by UNITAID and work by the TB Alliance and partners under the STEP-TB project grant, 
Macleods has introduced new pediatric FDCs. 
Macleods’s FDCs of HRZ (isoniazid, rifampin, and pyrazinamide) and HR (isoniazid and rifampin) are now 
available through the GDF and have been successfully registered in Côte d’Ivoire and India. Registrations are 
pending in Botswana, Burkina Faso, Cambodia, Cameroon, Congo, Ethiopia, Ghana, Kenya, Mozambique, 
Nigeria, the Philippines, Tanzania, Uganda, Vietnam, Zambia, and Zimbabwe.41 Registration is stalled in 
South Africa, as the Medicines Control Council requires bioequivalence work to be conducted in-country.42 
Rollout of the new pediatric FDCs is anticipated in Kenya and the Philippines before the end of 2016 and as 
part of a 100-site pilot program in India.43 Macleods has also received orders from Papua New Guinea and 
Kiribati and an inquiry from Zimbabwe.44
Other companies, including Lupin, Sanofi, Sandoz, and Svizera, are working on developing and introducing 
their own versions, albeit at varying paces and at the mercy of review and approval times of country regulatory 
authorities and WHO prequalification—a mechanism put in place to ensure and monitor the quality of 
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medications procured in bulk—and in the absence of approval by a Stringent Regulatory Authority, a 
requirement of manufacturers to sell medications through the GDF. 
Work to increase awareness and facilitate uptake of the new pediatric FDCs is being led by the TB Alliance, 
the WHO Global TB Program, and the WHO Department of Essential Medicines and Health Products. The 
UNITAID-funded STEP-TB project will come to an end in 2016, but UNITAID will continue to promote 
scale-up of the new pediatric treatment options and to support a more sustainable market, and it has issued a 
call for relevant proposals.45
Sanofi, the sponsor of rifapentine (indicated in the United States, in combination with isoniazid, for latent TB 
infection in children as young as two years), will perform a bioavailability and safety study of the components 
of its mango-flavored, fixed-dose dispersible of rifapentine and isoniazid and of a rifapentine stand-alone 
dispersible to facilitate dose adjustments in young children before the end of 2016. The Tuberculosis Trials 
Consortium will use these formulations in its pediatric PK and safety study of three months of once-weekly 
rifapentine and isoniazid (3HP) to prevent TB in children. The study (S35) is expected to open in 2017, and 
HIV-positive children on select ARV regimens will be eligible for participation.46,47 Unfortunately, rifapentine 
is still registered only in the United States; Sanofi has a long way to go to ensure wider access for adults and 
children (see “Tuberculosis Prevention Pipeline,” page 15).
 
Second-Line TB Drugs
Encouragingly, in August 2015, the WHO Expert Review Panel (ERP) issued an invitation to manufacturers 
to submit an expression of interest (EOI) to the WHO prequalification team for pediatric formulations of 
several second-line TB drugs, including cycloserine, levofloxacin, moxifloxacin, linezolid, and ethionamide.48 
Macleods expects to register pediatric formulations of these second-line drugs before the end of 2016.49 A 
pediatric formulation of clofazimine was not included in the invitation for EOI, but should be immediately 
added considering its increasingly important role as a component of MDR-TB treatment and trials of shortened 
regimens. A scored-dispersible or other novel pediatric formulation of clofazimine is urgently needed to 
facilitate dosing in small children; an invitation for an EOI from the WHO ERP for a pediatric formulation 
of clofazimine is a necessary first step. It is critical that these new formulations undergo palatability and 
acceptability evaluations in children and that their quality be assured. 
Still, even with the invited EOI and continued investments by Macleods to bring pediatric formulations 
for second-line TB drugs to market, without updated WHO dosing guidelines, future uptake by country 
programs is likely to be severely limited. The first time the WHO recommended doses for second-line TB 
drugs in children was 2006. In 2010, the WHO issued Rapid Advice: Treatment of Tuberculosis in Children,50 
which recommended increased doses of first-line TB drugs in children; in 2014, it updated its Guidance 
for National Tuberculosis Programs on the Management of Tuberculosis in Children.51 Yet neither of these 
updates considered data that have emerged for the use of second-line TB drugs in children since 2006. In 
fact, existing WHO guidelines do not include a recommended pediatric dose for clofazimine at all. The WHO 
should immediately take the steps necessary to issue updated, comprehensive, and evidence-based dosing 





Otsuka is using 5 mg and 25 mg dispersible tablets of delamanid in strawberry and cherry flavors in its PK 
and safety study, which is now enrolling children under five years of age (232; 233).
The bioavailability study for Janssen’s 20 mg dispersible tablet of bedaquiline has long been completed, and 
Janssen’s pediatric study finally opened to enrollment in May 2016. A second bioavailability study to evaluate 
differences between crushed and whole tablets of the adult formulation of bedaquiline (bedaquiline-crush) 
is under regulatory review in South Africa.52 Without access to Janssen’s pediatric formulation, these data are 
necessary to inform IMPAACT’s planned PK and safety study of bedaquiline in children, including those with 
HIV (P1108). Data from bedaquiline-crush will also be important to inform use of bedaquiline in children 
during the time between when evidence from pediatric PK and safety studies is available and when the 
pediatric formulation enters the market.
 
Table 3. Pediatric Formulations Newly Marketed and in Development























Ethambutol 100 mg Dispersible tablet Macleods
Isoniazid 100 mg Dispersible tablet Macleods
Pyrazinamide 150 mg Dispersible tablet Macleods
Rifapentine 100 mg Dispersible tablet Sanofi
Second-line and new drugs
Bedaquiline 20 mg Dispersible tablet Janssen




Ethionamide 125 mg Scored dispersible tablet Macleods
Levofloxacin 100 mg Scored dispersible tablet Macleods
Linezolid 150 mg Dispersible tablet Macleods




In recent years, significant strides have been made in pediatric TB research and development (R&D). Yet much 
work remains to collect critically important data in children, to increase access to the new pediatric FDCs, and 
to expedite development of, and access to, pediatric formulations for new and second-line TB drugs.
For researchers
•	Consider children when planning adult studies. Building PK investigations into studies that evaluate 
higher doses of TB drugs in adults is necessary to inform future PK targets in children.
•	Determine which PK value(s) correlate best with efficacy for TB drugs in children and establish PK targets 
based on adult data, taking into consideration the variability in severity and type of TB disease among, 
and challenges defining efficacy in, children.
•	Enroll children two years of age and younger in pediatric studies, as this is the period during which drug 
disposition changes the most for children, increasing risk for high or low drug exposures.
•	Include HIV-positive children in studies of new TB drugs and regimens. 
•	Include pregnant women in studies of new TB drugs and regimens.
For policy makers
•	Incorporate emerging data into guidelines for children more rapidly, especially those for new and 
second-line TB drugs in children.
For regulatory authorities
•	Enforce more thoughtful requirements to ensure comprehensive and timely investigations of TB drugs 
in children. Mandatory and time-bound pediatric investigational plans that also require studies in HIV-
positive children will help to shrink the persisting evidence and access gaps that exist between adults and 
children for new TB drugs.53
•	Follow the important precedent set by the EMA and allow parallel enrollment of pediatric cohorts in PK 
and safety studies.
•	Be transparent and clear about requirements to register pediatric formulations for both existing and new 
drugs. 
•	When possible and appropriate, consider waived requirements and registration fees to facilitate access.
For donors
•	Maintain and adequately fund momentum in pediatric TB drug R&D, for which global investments totaled 
$11.6 million in 2014.54 Recent attacks on the budget for and AIDS research priorities of the NIH are 
particularly concerning for pediatric TB R&D. Not only is the NIH the leading funder, but its investments 
support studies that are critical to improving treatment of pediatric TB and to filling both long-standing 
and new gaps in pediatric PK and safety data, especially for HIV-positive children taking ARVs.55
•	Further attention to and investments in pediatric TB trial infrastructure and site capacity development are 
urgently needed to support the increasingly full research agenda for prevention and treatment of TB in 
children. 
•	UNITAID, whose investments have led to the market introduction of appropriately dosed FDCs of first-
line TB drugs for children, and whose planned investments will ensure global uptake of these new 
formulations, should invest in a project modeled after STEP-TB that is focused on expediting development 
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